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CHAPTER I 
 
INTRODUCTION 
 
Overview 
  Since its discovery two decades ago, the Eph family of receptor tyrosine 
kinases (RTKs) has been implicated in an increasing number of physiological 
and pathological processes in various cell types and organs.  Recent genome-
wide studies in human cancer revealed that expression of Eph receptors are 
often dysregulated in many types of cancer and somatic mutations in tumors 
have been discovered in nearly all Eph receptors.  However, despite the clinical 
relevance of Eph receptor tyrosine kinases in human cancer, their precise roles 
in cancer are not well understood.  In breast cancer, EphA2 receptor is 
overexpressed in over 60% of tumor samples and high levels of EphA2 
expression are associated with poor patient prognosis.  Although roles of EphA2 
in tumor growth and metastasis have been reported in a number of tumor 
models, the function of EphA2 in mammary gland development and breast 
cancer-induced osteolysis in bone metastasis has not been investigated.  In my 
thesis work, we discovered that the EphA2 receptor plays a critical role in normal 
mammary epithelial proliferation and branching through regulating RhoA activity.  
Furthermore, we found that breast cancer cell-induced osteolysis is dependent 
on EphA2 function.  Our genetic, molecular, and pharmacologic approaches 
demonstrate that signaling through class A Eph RTKs, particularly EphA2, is 
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critical for normal breast epithelial growth and morphogenesis, as well as tumor-
induced osteolysis, providing a sound rationale for targeting EphA2 for new 
breast cancer therapies. 
 
The Eph Receptors and Ephrin Ligands 
 The Eph receptors comprise the largest family of receptor tyrosine kinases 
discovered in the human genome, consisting of 15 receptors and nine ligands 
(Table 1) [1]. The family is subdivided into two subclasses based on sequence 
homology, binding affinity, and structure of the ephrin ligand.  The A-subclass of 
receptors (EphA1-EphA10) bind to ligands tethered to the cell membrane by a 
glycosylphosphatidlinositol (GPI) anchor (ephrinA1-ephrinA6), while the B-
subclass (EphB1-EphB4, EphB6) bind to ligands containing a transmembrane 
domain followed by a short cytoplasmic region (ephrinB1-ephrinB3) (Figure 1).  
 The extracellular portion of Eph receptors contain a highly conserved N-
terminal ephrin-binding domain, a cysteine-rich region (including an epidermal 
growth factor-like motif) and two fibronectin type-III repeats. The Eph receptor 
cytoplasmic side is composed of a juxtamembrane segment, a classical protein 
tyrosine kinase domain, a sterile-α-motif (SAM) domain and a PSD95/Dlg/ZO1 
(PDZ)-binding motif (Figure 1). 
 
Eph Signaling  
 Engagement of Eph RTKs with ephrin ligands results in dimerization or 
oligomerization of receptor complexes on the cell membrane leading to 
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autophosphorylation of tyrosine residues throughout the intracellular portion of 
the receptor.  Phosphorylation of the receptor’s tyrosine amino acids within the 
juxtamembrane region releases the structural inhibition of the tyrosine residues in 
the kinase region permitting docking sites for downstream signaling molecules [3, 
4]. 
 Of the multiple signaling pathways affecting cell behavior mediated by Ephs 
and ephrins, the most commonly affected in breast cancer are Ras/MAPK, 
PI3K/AKT, and the small GTPases Rho/Rac/cdc42.  Several publications have 
reported the ability of EphA2 to activate Ras/MAPK signaling [5-7].  However, 
other reports have demonstrated EphA2 signaling can attenuate Ras/MAPK 
signaling highlighting a controversy that will be discussed in more detail below 
[8].  The involvement of the small GTPases with Eph receptors, especially Rho, 
is detailed in Noren and Pasquale ([9].  Similarly, studies from our lab suggest a 
role of crosstalk by EphA2 and ErbB2 receptors to enhance RhoA activity [5] as 
well as the ability of EphA2 stimulation and phosphorylation to activate RhoA and 
affect cell migration [10, 11].  Eph receptor signaling with PI3K/AKT has recently 
garnered attention as it demonstrates the complexity of Eph/ephrin signaling and 
the context in which the cellular interactions take place.  This will be discussed 
later, as well, but in short EphA2 is thought to regulate PI3K/AKT in breast 
cancer through p120RASGAP and inhibition of Ras [12]. 
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Table 1. Known Eph receptor tyrosine kinases and their ligands. 
Eph Receptors Ephrin Ligands 
A class 
EphA1 ephrinA1 
EphA2 ephrinA2 
EphA3 ephrinA3 
EphA4 ephrinA4 
EphA5 ephrinA5 
EphA6 ephrinA6 
EphA7  
EphA8  
EphA10  
B class 
EphB1 ephrinB1 
EphB2 ephrinB2 
EphB3 ephrinB3 
EphB4  
EphB5  
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Figure 1.  Eph receptor and ephrin ligands structure.  
A diagram dictating major domains of the Eph receptor and ephrin ligands.  The 
Eph receptor expressing cell is shown on the bottom in association with the 
ephrin-expressing cell on top.  From [2]. 
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 The ability of Eph receptors to signal has continued to grow due to recently 
discovered interactions with other RTKs.  Studies in our lab have demonstrated 
that EphA2 can physically interact with ErbB2, potentially increasing MAPK 
activation, while other labs have published reports of EphA2 and EGFR co-
immunoprecipitation leading to increased cell motility [5, 13].  Likewise, a study of 
EphA4 suggested that EphA4 can phosphorylate EGFR via EphA4 peptide 
substrate studies [14].  Not all Eph receptor crosstalk with other RTKs involves 
the EGFR family or is confined to the A class of Eph receptors.  Studies of EphB 
receptors revealed interaction with CXCR4 for AKT activation, as well as T cell 
recruitment through activation of the T cell receptor [15, 16].  Other examples of 
crosstalk are highlighted in Table 1.  The importance of these crosstalk pathways 
is the different signaling pathways that can be facilitated based on interactions 
and which receptor is activated.  The ability of other RTKs to be phosphorylated 
by Eph receptors or vice versa can have huge implications on therapies and the 
ability for resistance as recently described by Zhuang et. al. [17].    
 
Bidirectional Signaling 
 The Eph family of RTK and ligands are unique in their requirement of cell-cell 
contact to create ligand-receptor interactions.  They are further unique in their 
ability to signal through both the receptor expressing cell (forward signaling) as 
well as the ligand-expressing cell (reverse signaling) [1].  Eph signaling can 
control multiple functions in the cell:  cell morphology, adhesion, proliferation, 
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migration, invasion, as well as more specialized functions like synaptic plasticity, 
immune function and bone remodeling (focus of Chapter 3) [1, 18].  Forward 
signaling proceeds like a traditional receptor tyrosine kinase propagating a signal 
following kinase activity via ligand binding.  In contrast, reverse signaling occurs 
through the signal propagating through the ephrin ligand and ligand-expressing 
cell.  EphrinB reverse signaling originates through phosphorylation of tyrosine 
residues in the cytoplasmic region of the ligand following receptor interactions.  
This signaling is dependent on SRC family kinases [32].  Studies show ephrinA 
ligands can also mediate their own signaling cascades likely through modulating 
integrin function and/or co-clustering with signaling molecules in specific 
membrane microdomains (e.g. clathrin-coated pits) [33, 34].  The mechanisms, 
however, of reverse signaling for the ephrinA class of ligands are less 
understood since they are without a cytoplasmic region and are GPI-linked to the 
cell membrane.  Presumably, ephrinA-mediated reverse signaling requires the 
association of transmembrane signaling partners or internalization via a caveolin 
dependent mechanism.  
 
Ligand Independent and Dependent Signaling 
 The complexity in Eph-ephrin signaling not only comes from bidirectional 
signaling but also from the ability of the receptor to signal independently of ligand 
binding.  Many studies have been published showing classical receptor tyrosine  
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Table 2.  Crosstalk Between Eph Receptors and Other Receptors 
Eph Receptor Crosstalk Receptor Signaling  Outcome Reference 
EphA CXCR4 Receptor Cdc42 Inhibition [19] 
EphA Integrins Rac1 inhibition [20] 
EphA2 EGF Receptors Cell motility  [13] 
EphA2 Claudin4 Claudin4 
phosphorylation 
[21] 
EphA2 Integrins FAK inhibition [22] 
EphA2 E-cadherin EphA2 activation [23] 
EphA4 Integrins Integrin activation [24] 
EphA4 FGF Receptor MAPK activation [25] 
EphA4 EGF Receptor EGF receptor 
phosphorylation 
[14] 
EphA8 Integrins PI3K activation [26] 
EphB NMDA Receptor (at 
synapses) 
NMDA receptor 
phosphorylation 
[27] 
EphB E-cadherin E-cadherin  [28] 
EphB2 Syndecan-2 Syndecan-2 
phosphorylation 
[29] 
EphB2 L1 L1 phosphorylation [30] 
EphB2 and EphB4 CXCR4 Receptor AKT activation [16] 
EphB2 and EphB3 Ryk Receptor (WNT 
signaling) 
Tyrosine 
phosphorylation 
[31] 
EphB6 T Cell Receptor T cell activation [15] 
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kinase activation via ligand-dependent activity in signaling cascades.  Most of 
these studies demonstrate the ligand as inhibitory to their respective signaling 
pathway when bound:  Abl-Crk [35], Ras-Raf-MAPK [36], PI3K-Akt [37], integrin 
signaling [22] and small GTPase Rac activation [38].  Ligand independent 
signaling is demonstrated most often through crosstalk pathways involving Eph 
receptors.  A recent report proposed EGFR activation of EphA2 as an effector for 
cell motility absent of ephrin ligand [13].  Our lab has recently demonstrated the 
ability of another EGFR family member ErbB2 to crosstalk with EphA2 leading to 
activation needed for breast tumorigenesis and progression [5] [17].  Another 
group has reported a direct interaction and response between FGFR and EphA4 
as well as FGFR and EphA2 [25, 39].  
 Recent reports have demonstrated the ability of ligand-independent and 
ligand-dependent signaling to affect the same pathways in a manner that 
produces opposite outcomes.  This aids in understanding why dramatically 
different responses are seen under different contexts of oncogenic signaling.  
Ten years ago, Bing Cheng Wang’s group demonstrated that EphA2 activates 
focal adhesion kinase (FAK) in the absence of ephrinA1, while ephrinA1 
dependent activation of EphA2 results in dephosphorylation of FAK and 
inactivation via the SHP-2 phosphatase [36].  The most recent description of 
ligand independent and dependent signaling within the same pathway involves a 
regulatory loop involving phosphorylation of serine 897 in EphA2 by Akt [37].  
Activation of EphA2 with ephrinA1 suppresses Akt activation; limiting chemotactic 
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migration of glioma and prostate cancer cells, while EphA2 overexpression in the 
absence of ephrinA1 ligand promotes migration [37].  Thus, EphA2 is both an 
upstream negative regulator and a downstream activator of Akt depending on the 
presence or absence of ephrin ligand.   
 
Ephs and Ephrins in Development 
 Eph RTKs and ephrins are expressed in almost all embryonic tissues and 
have been implicated in neuronal and vascular development [18, 40, 41].  They 
were first reported as axonal guidance cues in retinotectal topography, where 
Eph receptor and ligand expression helped develop gradients in the developing 
embryo that resulted in a repulsive behavior for retinal axons.  This was 
demonstrated with temporal retinal axons expressing high EphA3 levels that 
would migrate and ultimately terminate in the anterior tectum where expression 
of its ligands, ephrinA2 and ephrinA5, was low [42, 43].  In vascular biology 
ephrinA1 transcripts were also detected in embryonic endothelial cells during 
embryonic development suggesting a role for the ligand in vasculature 
development [44-46].  EphrinA1 expression has also been detected in tumor 
vasculature as well as normal adult tissue vasculature by western blot 
(unpublished data).  Further, a recently developed ephrinA1 KO animal 
demonstrated heart value development defects [47].  B class Eph receptors and 
ligands are also involved in cardiovascular development.  EphB2, EphB3, EphB4, 
eprhrinB1 and ephrinB2 have all been implicated in the formation of the 
circulatory system in the mouse embryo [48-50].   
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 Furthermore, the expression of Ephs and ephrins have been documented in 
important developmental stages involved in epithelial development.  These 
developmental stages involve dispersal and rearrangement of the epithelia to 
promote gastrulation and segmentation.  This is accomplished by spatial and 
temporal specific expression of Ephs and ephrins to form gradients that serve as 
boundaries in development through attractive and repulsive forces.  For instance, 
EphA1 is expressed in varying combinations with ephrinA1 and ephrinA3 at 
different times in different regions during primitive streak formation where the 
germ layer will emerge [51].  Other epithelial based developmental features 
influenced by Ephs and ephrins include branched organs like the kidney, 
mammary gland, thymus and adult gut.  In the thymus, EphA4 deletion results in 
abnormal organization of thymic epithelial cells resulting in severely affected T 
cell development [52].  In vitro studies of MDCK cells have revealed an important 
role for EphA2 and ephrinA1 in kidney branching [53], whereas the same group 
has observed the expression of several ephrin ligands in tissue extracts from 
embryonic kidneys [54].  Battle et. al. demonstrated Eph and ephrin signaling 
regulation of intestinal cell positioning of the epithelium in a very elegant study of 
the adult gut [55].  Furthermore, EphB4, ephrinB2, and EphA2 have all been 
shown as critical in mammary development.  This is discussed in more detail 
below as well as serving as the focus of Chapter 2.   
Mammary Gland Development 
 The mammary gland is a dynamic organ that undergoes drastic changes via 
growth and remodeling in response to hormonal cues at puberty and pregnancy.  
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The early mouse mammary gland epithelium develops after mid-gestation when 
milk lines develop from the forelimb to the hindlimb along which placodes form as 
precursor nipples (reviewed in [56]).  Upon invagination by the placode into the 
mesenchyme, a rudimentary bud develops that later will support the mammary 
ductal tree.  This rudimentary ductal tree (anlage) continues to grow with normal 
body growth until puberty commences, at which time hormonal signals (estrogen, 
progesterone, etc.) will cause a robust increase in proliferation.  Upon hormonal 
stimulation, the epithelium responds by inducing proliferation at the tip of the 
epithelial duct in an area called the terminal end bud (TEB).  The TEB consists of 
multiple cell types including cap cells, body cells and myoepithelial cells (Figure 
2).  Other specialized epithelial cells line the lumen and are referred to as luminal 
cells.  These cells serve an integral part during lactation with the movement of 
milk through the ducts.  The TEB, lumen and the milk producing alveolar cells are 
only one part of two distinct tissue compartments that constitute the mammary 
gland.  The tissue surrounding the epithelial ducts is known as the 
stroma/connective tissue.  This second compartment is composed of fibroblasts, 
adipocytes and other structural components that make up the mammary fat pad.  
Interactions between developing epithelial ducts and their adjacent mesenchymal 
stroma help regulate mammary gland morphogenesis through endocrine 
hormones and local paracrine interactions.  Hormonal signaling induces 
proliferation at the distal tip of the TEB causing directional growth from the nipple 
while allowing bifurcation of the TEBs and secondary side-branches to sprout 
laterally from the trailing ducts.  As the epithelial duct proliferates and moves 
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through the mammary fat pad, cells composing the cap differentiate to form the 
lining of the duct or undergo apoptosis to form the lumen of the duct.  This 
process is continued until the entire fat pad is filled with a primitive ductal tree, 
upon which signals from the mesenchyme cause proliferation to cease.  This 
leads to the TEB regressing into a quiescent terminal end duct (TED). 
 Proliferation of the epithelial cells occurs again during pregnancy in 
response to hormonal signaling (i.e. estrogen and progesterone).  In order to 
meet the demand for milk production, the mammary epithelium undergoes 
dramatic expansion while simultaneously differentiating alveolar precursor cells 
into lobular alveoli that are capable of secreting milk for lactation.  The epithelium 
(including lobular alveoli) completely fills the mammary gland during lactation and 
will remain that way until the final stage of offspring development (Figure 3).   
Involution occurs when lactation ceases after the offspring are weaned and is 
marked by massive cell death (apoptosis) and remodeling of the alveolar 
compartment back to a quiescent state.  The return to this quiescent ductal state 
keeps the epithelium intact for subsequent rounds of pregnancy and lactation 
(reviewed in [57, 58]).   
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Figure 2.  Mammary gland structure and morphology.  (A) High magnification 
carmine alum-stained whole mount of TEB that has recently bifurcated to form 
two new primary ducts.  Two secondary side-branches are also present along the 
trailing duct (open arrowhead), as is an area of increased cellularity that may 
represent a nascent lateral bud (closed arrowhead).  Increased stromal cellularity 
is apparent around the bifurcating TEB. Scale bar 200mm.  (B). Hematoxylin and 
eosin-stained section of bifurcating TEB with an early lateral side-branch (closed 
arrowhead). Scale bar 100mm (Image courtesy of A.J. Ewald UCSF). (C) 
Schematic diagram depicting the major features of a bifurcating TEB.  Notable 
features include the considerable proliferative activity (mitoses) within the TEB, 
the single layer of TEB cap cells and multilayered pre-luminal body cells, the 
characteristic presence of a fibroblast-and collage-rich stromal collar surrounding 
the neck of the bifurcating TEB, and its conspicuous absence beyond the 
invading distal cap of each new TEB.  An increased number of macrophages and 
eosinophils is also shown.  Although there is no evidence that normal ductal cells 
ever cross the basal lamina, thinning of the basement membrane (dashed lines) 
at the leading edge of the invading duct may reflect partial enzymatic degradation 
and/or incomplete de novo synthesis of the basal lamina.  (From [57]) 
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 The ability of the mammary gland to replenish cells through cycles of 
pregnancy, lactation and involution has been attributed to stem cells found in the 
mammary gland ([59], reviewed by [60]).  Studies have shown epithelial cells are 
lost during development as they differentiate into alveolar or ductal systems.  
They are also lost due to shedding into the milk during lactation.  Mammary gland 
integrity must be maintained through replacement of these cells.  Studies have 
revealed the existence of self-renewing multipotent mammary stem cells and 
transplantation studies of epithelium fragments in mice and rats, upon removal of 
endogenous epithelial components, have clearly demonstrated their renewing  
capabilities [60-63]. 
 
 Eph Receptors in Mammary Gland Development 
 Mammary epithelial morphogenesis is a complex developmental process 
during which extensive networks of branched ducts form from a rudimentary 
epithelial bud.  This process is termed branching morphogenesis and is regulated 
by endocrine hormones and local paracrine interaction between the developing 
epithelial ducts and their adjacent mesenchymal stroma.  Expression of multiple 
Eph family receptors and their ligands has been reported in the mammary gland.  
Ephrin-B2 is expressed on the luminal cells, and its receptor, EphB4, is 
expressed complementarily on myoepithelial cells in mice.  The expression of 
EphB4 and ephrinB2 is dependent on estrogen and is regulated during the estrus 
cycle [65].  Forced overexpression of EphB4 under the control of the mouse.
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Figure 3.  Mammary gland development during puberty, pregnancy and 
lactation.  Schematic (a-d) presentation of the different stages of mammary 
gland development.  A rudimentary ductal design within the mammary fat pad is 
visible at birth, which grows at the same rate as the animal until the onset of 
puberty.  (a) During puberty, cyclical hormone production accelerates ductal 
outgrowth causing club-shaped structures (TEB) where the highest levels of cell 
division occur to appear at ductal tips.  (b) In mature virgin, the entire fat pad is 
filled with a regularly spaced system of primary and secondary ducts, with side 
branches that form and disappear in each oestrous cycle.  (c) Hormonal changes 
that occur when pregnancy begins increase cell proliferation and the formation of 
alveolar buds.  (d) During lactation, alveoli are fully matured and the luminal cells 
synthesis and secrete milk components in the lumina.  Following lactation the 
mammary gland will undergo massive apoptosis during involution to revert back 
to a mature virgin gland structure.  (From [64]). 
18 
 
 
mammary tumor virus (MMTV) promoter/enhancer induced a delayed 
development of the mammary epithelium at puberty and during pregnancy, with 
untimely epithelial apoptotic cell death during pregnancy and abnormal epithelial 
DNA synthesis at early post-lactation involution, indicating a disturbed response 
to proliferative/ apoptotic signals [66]. 
 In addition to EphB4, developmentally controlled expression of EphA2 in the 
mammary epithelium has also been reported [67, 68].  Loss of EphA2 receptor 
resulted in decreased penetration of mammary epithelium into the fat pad and 
reduced epithelial proliferation and inhibition of epithelial branching, suggesting a 
positive role for EphA2 during normal mammary gland development [69].  EphA2 
is also expressed in human mammary epithelial cells [10, 70-72].  Fournier et al. 
analyzed gene expression in two non-malignant human mammary epithelial cell 
lines in 3D cultures.  When these cells underwent growth arrest and differentiated 
into polarized acini, EphA2 levels were significantly decreased [73].  This is 
consistent with the observation that EphA2 is expressed at low levels in normal 
mammary gland epithelium, whereas expression increases in breast cancer [74].  
Indeed, analysis of a set of 19 genes that were down regulated in differentiated 
acini of human mammary epithelial cells in 3D cultures against 2 independent 
breast cancer microarray datasets revealed that increased EphA2 levels are 
associated with poor patient prognosis [72, 73].  Taken together, these data 
suggest that EphA2 is required for mammary gland morphogenesis and 
increased EphA2 expression in human breast cancer is associated with tumor 
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cell malignancy and poor patient survival. 
 
Dysregulation of Ephs and Ephrins in Cancer 
 As previously stated, multiple Ephs and ephrins have critical roles in prenatal 
and postnatal development.  Due to the fact that many cancer studies have 
revealed that aberrant developmental signaling pathways often contribute to 
tumorigenesis, a strong push was made looking into the potential for 
dysregulation of Eph and ephrin signaling in cancer.  Eph receptors are often 
overexpressed in many human cancers, including melanomas, sarcomas, 
leukemias, brain tumors, and breast cancer [75].  Current data demonstrate that 
Eph receptors and ephrins function in both tumor cells and the tumor 
microenvironment, with dual roles in tumor suppression and tumor promotion.  
These observations suggest the feasibility in screening for Eph receptors and/or 
ligands as predictors of prognosis in patients.  EphA2, for example, has been 
linked to increased malignancy and poor clinical prognosis in breast cancer [72], 
non-small cell lung cancer [76], esophageal squamous cell carcinoma [77], 
cervical squamous cell carcinoma [78], renal cell carcinoma [79], glioblastoma 
multiforme [80], and endometrial cancer [81].  Overexpression of EphA4 in 
gastric cancer is associated with shorter survival [82] and increased expression 
of EphA7 is associated with adverse outcome in primary and recurrent 
glioblastoma multiforme [83].  Poor prognosis and/or reduced survival is not only 
associated with the A class of receptors.  Reports on EphB4 overexpression 
suggest poor overall survival in patients with ovarian cancer and head and neck 
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squamous cell carcinoma [84, 85].  Using the van de Vijver dataset we were able 
to confirm that elevated levels of EphA2 were associated with increasing 
malignancy and poor prognosis in breast cancer, as well as being mutually 
exclusive for EphA2/ephrinA1 expression in metastatic cancer (Figure 4, 
unpublished data).   
 
Role of Eph Receptor in Breast Cancer Promotion  
 Results from high throughput screens revealed many Eph receptors were 
overexpressed in multiple types of human tumors [1, 74].  However, in breast 
cancer, the number of Eph receptors found to be expressed were limited to 
EphA2 and EphB4, the two Eph receptors most extensively studied with highest 
degree of aberration [86].  EphA2 is expressed at low levels in normal human 
breast epithelium [67, 87] and overexpressed in 60-80% of breast cancers [70, 
71, 88](Brantley-Sieders and Chen, unpublished data).  Experimentally induced 
overexpression of EphA2 resulted in malignant transformation of non-
transformed MCF10A breast cells and enhanced malignancy of pancreatic 
carcinoma cells [71].  Conversely, siRNA-mediated inhibition of EphA2 
expression impaired malignant progression of pancreatic, ovarian and 
mesothelioma tumor cell lines, and overexpression of dominant-negative EphA2 
constructs suppressed growth and metastasis of 4T1 metastatic mouse  
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Figure 4.  Kaplan-Meier analysis for EphA2 in breast cancer. Recurrence 
survival and overall survival was defined as death due to any cause. (log-rank 
test) from Van de Vijver et. al. [93] 
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mammary adenocarcinoma cells in vivo [11, 89-91].  To determine whether 
EphA2 plays a causative role in breast cancer initiation and metastatic 
progression, EphA2 knockout mice were crossed to MMTV-Neu transgenic 
animals that express a rat homologue of the ErbB2 receptor tyrosine kinase.  
Loss of EphA2 impairs both tumor initiation and lung metastasis in MMTV-Neu 
mice [5].  Similarly, EphB4 levels are also elevated in human breast cancer [87].  
EphB4 knockdown inhibited breast cancer survival, migration, and invasion in 
vitro and tumor growth in a xenograft model in vivo [92].  Furthermore, 
overexpression of EphB4 in the mammary epithelium accelerates tumor onset 
and lung metastasis in MMTV-Neu animals [66].  Taken together, these studies 
indicate a role for Eph receptor in tumor promotion.  
 Although previous studies indicate a role for Eph receptors in tumor 
promotion, the mechanisms regulating this oncogenic function are not entirely 
clear.  In many instances, Eph receptors in tumor cells are underphosphorylated 
in spite of overexpression.  This could be due to increased activity of 
phosphotyrosine phosphatases or loss of E-cadherin in tumor cells.  As E-
cadherin regulates cell surface localization of EphA2 and/or loss of cell-cell 
contacts prevent interaction with endogenous ephrin ligands, which often results 
in internalization/degradation of receptors after activation by ligand [23, 94, 95].  
As both Eph receptors and ligands are membrane anchored and reside in 
separate microdomains on the cell surface, loss of cell-cell adhesion in tumor 
cells impairs activation of Eph receptors by ephrins on adjacent cells [96, 97].  
Thus, the oncogenic activity of Eph receptors appears to be ligand independent.  
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High levels of EphA2 receptor have been shown to physically and functionally 
interact with the EGF receptor and ErbB2, promoting Erk and RhoA GTPase 
activity [13].  These data suggest that crosstalk between Eph receptors and other 
oncogenic pathways promotes tumor cell malignancy in an ephrin-independent 
manner.  Furthermore, a high level of EphA2 was found to upregulate matrix 
metalloproteinase 2 (MMP2) [98] and extracellular matrix protein fibronectin [99].  
Modulation of tumor cell interaction with the microenvironment may also 
contribute to Eph receptor function in tumor promotion. 
 
Role of Eph Receptors in Tumor Suppression 
 Many studies demonstrate a role of Eph receptors in tumor suppression.  
Stimulation of EphA receptors with soluble ephrinA1-Fc ligand reduced Erk 
phosphorylation in tumor cell lines, fibroblasts, and primary aortic endothelial 
cells and suppressed growth of primary keratinocytes and prostate carcinoma 
cells [8, 36].  Macrae et al. also reported that treatment of human breast cancer 
cell lines with ephrinA1-Fc attenuated EGF-mediated phosphorylation of Erk and 
inhibited transformation of NIH3T3 cells expressing v-erbB2 [8].  In addition, 
EphA2-deficient gene-trap mice displayed increased susceptibility to chemical 
carcinogen-induced skin cancer, accompanied by increased tumor cell 
proliferation and phosphorylation of Erk [100].  These data suggest that ephrin-A-
induced EphA2 receptor forward signaling inhibits tumor malignancy. 
 In addition to EphA2, EphB4 forward signaling also appears to inhibit tumor 
progression.  Systemic delivery of ephrinB2-Fc inhibits the growth of MDA-MB-
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435 tumor xenografts [35].  EphB4 forward signaling activates the Abl/Crk 
pathway to inhibit tumor cell growth and motility in breast cancer cells [35].  
Furthermore, EphB receptor signaling is also able to suppress tumor expansion 
in colon cancer.  Overexpression of a dominant negative EphB2 cytoplasmic 
truncation mutant or knockout of EphB3 or ephrinB1 in the intestinal epithelium 
significantly increases tumor numbers and tumor invasiveness in the APCmin/+ 
model [28, 101].  EphB receptors have been proposed to compartmentalize the 
expansion of colon cancer cells through a mechanism dependent on E-cadherin–
mediated adhesion [28].   
 In summary, ephrin-induced Eph receptor forward signaling in non-
transformed mammary epithelial cells appears to transduce an inhibitory signal 
that may keep cells quiescent and non-invasive [8, 35, 36].  Upon tumor initiation, 
Eph receptor expression is up-regulated by oncogenic signaling pathways such 
as the Ras-MAPK pathway in breast cancer or the Wnt-ß-catenin pathway in 
colon cancer, whereas their ephrin ligands are often downregulated [8, 55] or 
unable to bind to receptor due to loss of cell-cell adhesion [23].  Crosstalk 
between elevated Eph receptors and other oncogenes, such as the ErbB family 
of receptor tyrosine kinases leads to enhanced cell proliferation and 
tumorigenesis, presumably independently of ephrin stimulation [13]. 
 
Eph Receptors and Ephrins in Tumor Angiogenesis 
 Tumor angiogenesis is critical for growth, survival, and malignant progression 
of tumors. Tumor vessels not only supply the nutrients and oxygen necessary for 
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tumor cell growth and survival, but also actively promote malignant progression 
by providing an entry point into the circulation for the dissemination of metastatic 
cells [102].  In addition to regulating developmental angiogenesis, Eph receptors 
and ephrins have also emerged as critical regulators of tumor angiogenesis.  The 
first ligand discovered for the Eph receptors, ephrinA1, is a tumor necrosis factor 
alpha (TNF- ) inducible gene in endothelial cells [103].  Early studies 
demonstrated that ephrinA1 promotes angiogenic responses in vitro and corneal 
neovascularization in vivo.  EphrinA1 is expressed in developing embryonic and 
tumor vasculature [45, 70, 87].  More importantly, ephrinA1 is further induced by 
hypoxia in tumors that are resistant to anti-VEGF therapy [104].  Interestingly, in 
recently generated ephrinA1 KO animals, mice deficient for the A1 ligand survive 
to adulthood with only minor heart valve defects [47], suggesting that other 
ephrinA ligands can functionally compensate for the loss of ephrinA1 in vascular 
development.  It remains to be determined whether tumor angiogenesis is 
affected in these mice.   
 EphA2, a major receptor for ephrinA1 in vascular endothelial cells, plays a 
significant role in promoting tumor angiogenesis.  Implantation of tumor cells 
subcutaneously or into the mammary gland of EphA2-deficient host mice results 
in reduced tumor volume, microvascular density, and lung metastasis [105]. 
These results suggest that loss of EphA2 in the tumor microenvironment impairs 
tumor angiogenesis and metastatic progression [105, 106].  Indeed, EphA2-
deficient vascular endothelial cells fail to migrate and assemble in response to 
angiogenic cues in vitro and are unable to incorporate into tumor blood vessels 
26 
 
when they are co-transplanted with tumor cells in vivo [106, 107], indicating a 
critical function for EphA2 in tumor angiogenesis.  In contrast to the complex 
effects of Eph signaling in tumor cells, ephrin-Eph bi-directional signaling in 
vascular endothelial cells promotes tumor angiogenesis.  Brantley-Sieders et al. 
showed that EphA2 receptor forward signaling regulates endothelial cell 
migration and assembly through PI3 kinase-mediated Rac1 GTPase activation 
[106].  A yeast two-hybrid screen for EphA2 interacting proteins revealed that 
Vav2 and Vav3 guanine nucleotide exchange factors are recruited to activated 
EphA2 receptor and subsequently elevate Rac1-GTP levels [48].  Loss of Vav2 
and Vav3 inhibits Rac1 activity and ephrinA1-induced angiogenic responses both 
in vitro and in vivo [48].  Furthermore, Fang et al. mapped phosphorylated 
tyrosine residues of EphA2 in vascular endothelial cells [3].  EphrinA1-induced 
phosphorylation of Y587 and Y593 in the EphA2 receptor recruits Vav2 and Vav3 
exchange factors, whereas phosphorylation of Y734 provides a docking site for 
the p85 regulatory subunit of PI3 kinase [107].  EphA2-null endothelial cells 
reconstituted with EphA2 mutants lacking these binding sites fail to activate Rac1 
GTPase, are defective in cell migration and assembly in vitro and are unable to 
incorporate into tumor vasculature in vivo.  These results suggest a critical role 
for these tyrosine phosphorylation sites in transducing EphA2 forward signaling 
in vascular endothelial cells and validate the involvement of PI3 kinase-
dependent activation of Vav exchange factors and Rac1 GTPase in ephrinA1-
induced angiogenesis.   
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 Gene targeting studies have established ephrinB2 and EphB4 as key 
regulators of embryonic vascular development [49, 108].  EphrinB2 expression 
has also been observed in tumor vasculature in a variety of tumor types, 
suggesting that this ligand may regulate tumor neovascularization [108-110].  In 
support of this hypothesis, A375 melanomas form smaller, less vascularized 
tumors in the presence of the soluble, monomeric EphB4 extracellular domain in 
vivo [111].  Soluble EphB4 may act, at least in part, by preventing binding of 
tumor cell EphB receptors to ephrinB2-positive endothelium, thus disrupting 
tumor angiogenesis.  Further support for this hypothesis is provided from studies 
in which overexpression of a truncated cytoplasmic deletion EphB4 receptor 
construct produced increased tumor growth and vascularity in mammary tumors, 
likely through ephrinB2 mediated reverse signaling in host endothelium [110].  
Upregulation of ephrinB1 expression has been reported in hepatocellular 
carcinoma, and overexpression of ephrinB1 enhances tumor neovascularization 
in vivo [112].  Although proliferation of ephrinB1 overexpressing cells was not 
affected in culture, soluble ephrinB1-Fc enhanced endothelial cell proliferation 
and migration in vitro, suggesting that at least one function of ephrinB1 in tumor 
progression involves facilitation of tumor angiogenesis [112, 113].  Taken 
together, these studies reveal a critical role for B class receptors and ligands in 
tumor progression and vascular recruitment for multiple types of human cancer. 
 
Breast Cancer Metastasis 
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 Although the overall five-year survival rate has increased due to early 
detection and advances in treatment, women diagnosed with more advanced 
and/or aggressive forms of breast cancer have only about a quarter chance of 
reaching the five-year survival mark.  This low survival rate is usually not due to 
the primary tumor, but is often a result of cancer cells disseminating to distant 
organs [114, 115].  These disseminating cancer cells from primary breast tumors 
often colonize the same sites: lung, liver, brain, and bone [116].  This 
characteristic ability of breast cancer cells to metastasize to certain organs but 
not others was first observed by Stephen Paget who argued distribution 
compatibilities between disseminated tumor cells (the seed) and certain organs 
(the soil) could not be merely by chance [117].  Despite the more than a century 
of research following Paget’s metastasis theory, our knowledge of the molecular 
mechanisms underlying breast cancer metastasis to specific organ sites such as 
bone remains limited.  
 The skeleton is a favored site of metastasis for many tumors.  Studies show 
approximately 70% of patients that die from breast or prostate cancer have bone 
metastasis [118].  Metastasis to bone is often undetected in early stages of 
breast cancer but at later stages it can invariably lead to bone pain, nerve 
compression, and bone fractures, with extensive bone destruction leading to 
hypercalcemia that increases the mortality and morbidity of patients [118].  
Despite our current understanding of bone development and the aberrations 
associated with breast cancer, only palliative treatment options are available to 
the patient once metastases are discovered in the bone, as there is no cure. 
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Physiology of the Bone:  Bone Components 
 Bone is a specialized type of connective tissue that provides structural 
support, protective functions, and regulation/reservoir of calcium and growth 
factors in the body [119].  Two types of bone are present within the skeleton, 
cortical and trabecular.  Both types contain the same composition, mostly type I 
collagen with a few non-collagenious proteins like osteopontin (OPN) and 
osteocalin, though they are organized differently to provide for different functions 
within the skeleton [119].  Cortical bone is dense and tightly compacted to serve 
as a protective layer around the bone and while also serving to support the 
weight load of the body.  In contrast, trabecular bone is loosely organized and 
porous.  It is located in the interior of the bone near the ends, and is metabolically 
active and will undergo a higher turnover rate than cortical bone [119].  Long 
bones in the body are divided into three portions of the diaphysis, metaphysis, 
and epiphysis.  The ends of the bone, ephiphysis, are located above the growth 
plate and are the portion of the bone that elongates during growth.  The 
diaphysis is the long narrow portion of the bone composed mainly of cortical 
bone, in contrast to the metaphysis, located just below the growth plate, 
composed predominantly of trabecular bone (Figure 5).   
 
Bone Resorption 
 Bone remodeling takes place throughout life and is necessary for structural 
maintenance and skeletal repair as well as for calcium homeostasis.   
30 
 
The process of remodeling consists of coupled processes of bone resorption and 
formation, discussed in detail later.  The sequence of events mediating 
remodeling occurs synchronously throughout the skeleton and the resorption of 
“old” bone to be replaced with “new” bone occurs in the same place at the same 
time so there are no changes to the shape of the bone.  The importance of local 
control on this process through cytokine and hormonal regulation can be 
demonstrated through genetically engineered animal models designed to under- 
or over-express cytokines, hormones and/or their receptor [120].   
 Constant remodeling of bone is facilitated by three cell types:  osteoblast, 
osteoclasts and osteocytes.  Together, these cells tightly regulate bone 
resorption and deposition.  Osteoblasts are derived from mesenchymal stem 
cells and synthesize new bone by providing for the new bone matrix and aiding in 
mineralization of this new matrix.  Osteoblast precursors (MSC’s) can be induced 
to proliferate and differentiate into mature osteoblasts through cell-cell 
interactions, cell-extracellular matrix contacts, and many soluble factors such as 
chemokines, cytokines, hormones and growth factors [121].  Transcription factors 
RUNX2 and OSTERIX, bone morphogenic proteins (BMPs), and local growth 
factors (IL-1, TNFα, PTH) all stimulate differentiation of osteoblasts and bone 
formation [122-124].  After synthesis of new bone, mature osteoblasts either 
undergo apoptosis or become embedded in the bone as osteocytes.  During 
bone deposition, osteoblasts secrete multiple factors (BMPs, IGF, TGF-β, and 
FGF) that become incorporated into the bone thus making bone a rich reservoir 
of growth factors. 
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 Osteocytes, which are derived from osteoblast embedded in the bone matrix, 
determine the location of osteoclasts in the bone.  It is believed that osteocytes 
can sense microcracks and microfractures in the bone as well as mechanical 
load deficiencies that trigger osteoclasts differentiation and recruitment (reviewed 
in [125, 126]). 
 Osteoclasts are cells responsible for bone degradation (osteolysis) and are 
derived from hematopoietic stem cells, which also give rise to monocytes, 
dendritic cells and macrophages [127, 128].  Osteoclasts form from precursor 
cells fusing together in response to proliferation (often induced by M-CSF) 
resulting in large multinucleated cells [129] (Figure 6).  Osteoclasts become 
functional and are activated by RANKL expressed on osteoblasts or released by 
osteoblasts.  These activated osteoclasts bind to the bone matrix through integrin 
binding by αvβ3, αvβ5, and α2β1 [127, 128].  The sealed compartment formed 
between the bone surface and the osteoclast is created by reorganization of the 
actin cytoskeleton in the osteoclast [127, 128].  In this sealing zone an acidic  
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Figure 5. Long Bone Anatomy.  Diagram of a long bone indicating the major 
regions and the major structures within the metaphysis, i.e. trabecular bone, 
cortical bone, growth plate and the sinusoidal endothelium.  Adapted from [123] 
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 environment is achieved by the action of a v-type H+-ATPase electrogenic 
proton pump and Cl- channel [127, 128].  Proteolytic enzymes, like cathespin K, 
degrade the bone matrix, mostly type I collagen, which is exposed as a result of 
acidification [130]. 
 
Bone Remodeling 
 Bone remodeling is a critical, tightly regulated process responsible for 
replacing damaged or old bone with new bone [131].  The coupling of bone 
resorption with bone formation during remodeling helps in achieving a balance 
between the two as different cells are responsible for different functions.  
Dysregulation of this coupling can lead to many pathological conditions like 
osteoporosis, osteopetrosis, and rheumatoid arthritis.  In order for coupling to 
occur osteoclast and osteoblasts must communicate (reviewed in [132]).  There 
are three models for communication between osteoclasts and osteoblasts.  1.  
Osteoclasts and osteoblasts can make direct contact allowing membrane-bound 
receptors and ligands to interact and induce activation of intracellular pathways.  
2.  Osteoclasts and osteoblasts can form gap junctions that allow for the diffusion 
of small water-soluble molecules between the cells.  Signaling via paracrine 
activity of growth factors, cytokines, and chemokines can also occur this way.  3.  
Liberated growth factors from osteoclast resorption of bone can lead to 
communication between the cells in form of positive and negative feedback loops 
[133].   
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Figure 6.  The osteoclast is a member of the monocyte/macrophage family.  
Early nonspecific differentiation along the osteoclast pathway is dependent on 
PU.1 and the MITF family of transcription factors, as well as the macrophage 
proliferation and survival cytokine M-CSF.  Activation of RANK by osteoblast-
expressed RANK ligand (RANKL) commits the cell to the osteoclast fate, which is 
mediated by signaling molecules such as AP-1 transcription factors, tumor 
necrosis factor receptor associated factor 6 (TRAF6), nuclear factor B (NF B),  
c-Fos and Fra-1.  RANKL-stimulated osteoclastogenesis is inhibited by the 
RANKL decoy receptor osteoprotegerin (OPG).  The initial event in development 
of the resorptive capacity of the mature osteoclast is its polarization, which 
requires c-Src and the v 3 integrin.  Once polarized, the osteoclast mobilizes 
the mineralized component of bone.  Bone mobilization is achieved through the 
acidifying molecules, carbonic anhydrase II (CAII), an electrogenic H+ATPase 
and a charge-coupled Cl- channel.  Cathepsin K mediates bone organic matrix 
degradation.  (From [130]) 
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 Soluble factors like PTH, PTHrP, TNFα, Il-1, IL-11, PGE2, and 1,25-(OH)2 
vitamin D3 can enhance osteoclastogenesis through RANKL-mediated induction 
of osteoblasts [132].  Using genetically manipulated mice and soluble RANKL for 
rescue, it is well established that RANK signaling is critical for osteoclastogenesis 
[134, 135].  The same osteoblasts that can induce osteoclast differentiation via 
RANKL can inhibit osteoclastogenesis by release of a decoy receptor for RANKL, 
OPG [136].  The ratio of OPG:RANKL is indicative of osteoclastogenesis activity 
with more OPG interfering with osteoclasts-osteoblasts interactions to inhibit 
differentiation and fusion of osteoclast precursors.   
 
The “Vicious Cycle” of Bone Metastasis 
 In order for a primary breast tumor to metastasize to a distant organ i.e. bone, 
tumor cells from the primary tumor must go through a series of coordinated 
steps.  Breast cancer cells must invade the surrounding host stromal tissue and 
break away from the primary tumor, intravastate into the blood stream, survive in 
the blood stream, adhere to the blood vessel wall, extravastate from the blood 
circulation, and colonize this secondary (metastatic) site (Figure 7).  Multiple 
genes regulate the ability of cells to undergo metastasis and this is reviewed 
nicely in [116].   
 Once breast tumor cells have established themselves in the bone 
microenvironment they encounter a permissive environment for growth via the 
richness of growth factors, cytokines, and chemokines that are stored or present 
in the bone.   These factors induce tumor cell growth that allows for the release 
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of PTHrP, IL-1, -6, -8, and -11 that activates osteoblast to produce RANKL.  
RANKL secreted from osteoblasts binds to the RANK receptors on osteoclast 
inducing  
differentiation, activation, and resorption of the bone.  Growth factors like TGF-β 
and IGF plus minerals like calcium (Ca2+) are released from bone when it is 
degraded, which stimulates the growth of cancer cells with subsequent release of 
more PTHrP and interleukins thus establishing a positive feedback loop (Figure 
8).  Therefore, osteolytic lesions ultimately result from sustained osteoclast 
activation uncoupled from bone restoring osteoblast function [137].   
 
Eph Receptors in Bone Biology 
 A role for ephrin ligands and Eph receptors in bone biology was recently 
discovered.  The first example of Eph receptors and ephrin ligands in bone 
biology was established in the B class with the studies presented by Compagni et 
al.  Using an ephrinB1 knockout mouse model the investigators were able to see 
skeletal abnormalities including cleft palate, skull shortening, asymmetric pairing 
of the ribs, and sternebral fusions [138].  Other studies of ephrinB1 knockout 
mice by an independent group revealed similar skeletal abnormalities including 
limb bud and digit malformations [139].  Furthermore, ephrinB1 mutant mice with 
targeted PDZ biding mutations revealed the ephrinB1 ligand was targeted to cells 
in the mesenchymal lineage and cells expressing the ephrinB1 mutation had 
decreased bone mass and size [140].  Human studies have found ephrinB1 
genetic mutations are associated with craniofrontonasal syndrome [141, 142].  
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Recent studies have demonstrated that ephrinB2 expressed on osteoclasts is 
inhibitory for osteoclast differentiation in contrast to EphB4 on osteoblasts being 
stimulating [143].  A class Eph receptors have also recently been implicated in 
bone homeostasis.  A recent report has demonstrated the role of EphA4 as a 
guidance cue for osteogenic precursor cells during calvarial bone growth through 
Twist1 [144].  Irie et. al. have shown the ephrinA2-EphA2 interaction between 
osteoclast precursors and osteoblasts enhances osteoclastogenesis while 
inhibiting osteoblast differentiation [145].  
 
Eph Receptors in Cancer-Induced Bone Disease 
 The increasing evidence of Eph ligand and receptor activities in bone biology 
raises the possibility of these Eph and ephrin interactions having a role in 
aberrant bone remodeling.  Breast cancer and multiple myeloma are associated 
with bone metastases that exhibit high levels of osteolysis while prostate cancers 
usually have higher levels of bone formation.  In multiple myeloma, osteolysis is 
driven by lack of EphB4 expression on osteoblasts causing an inhibition of new 
bone.  A class Eph receptors and ephrin ligands are also implicated in cancer-
induced bone dysregulation.  A tissue microarray of prostate cancer metastasis 
foci in lymph node, liver, and bone revealed a decrease expression level of 
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Figure 7.  The steps involved in tumor-cell metastasis from a primary site to 
the skeleton.   The primary malignant neoplasm promotes new blood vessel 
formation, and these blood vessels carry the cancer cells to capillary beds in 
bone.  Aggregates of tumor cells and other bloods cells eventually form 
embolisms that arrest in distant capillaris in bone.  These cancer cells can then 
adhere to the vascular endothelial cells to escape the blood vessels.  As they 
enter the bone, they are exposed to factors of the microenvironment that support 
growth of metastases.  (From [114]).  
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Figure 8.  Vicious cycle of bone metastasis.  Tumor cells secrete PTHr-P 
which stimulates bone resorption via RANKL expression in osteoblastic cells.  
Bone resorption results in release of growth factors such as TGF  and calcium 
from the extracellular matrix.  Calcium and TGF  both feedback to tumor cells to 
increase PTHr-P production that amplifies favorable signals for tumor localization 
in bone [146]. 
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ephrinA1 in bone metastasis [147].  Likewise studies have implicated A class 
receptors in giant cell tumors [148], and prostate cancer metastasis [149].  
 
Cytokine Signaling and Growth Factors in Bone Metastasis 
 The formation of bone metastasis requires significant alteration of the balance 
between bone formation and bone resorption.  In many cases this imbalance is 
achieved through tumor cell production of hormones, growth factors, chemokines 
or cytokines that contribute to further propagation of aberrant behavior by bone 
cells.  Some of these factors are:  TNF , PTHrP, PGE2, IL-1, IL-6, IL-8, IL-11, IL-
15, IL-17, LIF, and Oncostatin M [150-152]. TNF  is expressed primarily by 
activated macrophages and directly regulates recruitment of osteoclast 
precursors to sites of resorption.  PTHrP is an osteoclast activating factor and its 
overproduction has been documented in skeletal metastases from breast cancer 
versus non-skeletal metastases from breast cancer [146].  Stromal components 
are responsible for the increase in PTHrP levels and the higher levels allow 
binding of its receptors on osteoblasts, which in response secrete RANKL and 
MCSF resulting in more osteoclast differentiation and bone resorption.  Many of 
the interleukins under study for roles in breast cancer and bone metastasis are 
pro-inflammatory cytokines.  IL-1 is expressed by activated macrophages and 
has been shown to stimulate RANKL expression and pit formation [153].  IL-6 
also contributes to the local inflammatory response but can also contribute to 
bone resorption by inducing production of RANKL by osteoblasts upon binding.  
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Further, IL-6 induces tumor cells to produce PTHrP, IL-8, and IL-11.  These later 
interleukins, as well as IL-15 and IL-17, are also all able to induce macrophage 
recruitment subsequent osteoclast migration and osteoclast activation through 
inducing RANKL release.   
 
Eph Receptors as Targets for Breast Cancer Therapeutics 
 Since Eph receptors are often overexpressed in malignant cancer and 
reduction of Eph receptor levels was found to be efficacious in tumor inhibition in 
animal models, a wide range of therapeutic strategies targeting Eph receptor has 
been recently developed for cancer treatment.  These approaches include 
activating monoclonal antibodies against Eph receptors, ligand- or activating 
antibody cytotoxin conjugates, small interfering RNAs (siRNA), antagonistic 
peptides, small molecular inhibitors, and immunotherapy (Table 2). 
 Carles-Kinch et al. first reported that activating monoclonal antibodies against 
EphA2 inhibited tumor growth in soft agar and prevented tubular network 
formation on Matrigel [113].  Coffman et al. subsequently showed that similar 
anti-EphA2 agonistic antibodies selectively bind epitopes on malignant cells and 
decreased tumor growth in xenograft tumor models [154, 155].  The mechanism 
of action of these antibodies appears to mimic ephrin ligands, inducing receptor 
phosphorylation and subsequent internalization and degradation [113, 154, 155].  
However, it is not clear if agonistic antibody-induced EphA2 receptor forward 
signaling also conveys an inhibitory signal to promote tumor suppression.  
Regardless, the ability of ephrins and anti-EphA2 antibodies to distinguish 
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malignant from non-malignant cells prompted the development of ligand- or 
agonistic antibody-toxin conjugates.  Wykosky et al. reported a novel cytotoxin 
composed of the ephrinA1 ligand conjugated to a genetically modified bacterial 
toxin, Pseudomonas exotoxin A [156].  EphrinA1-conjugates exhibits potent and 
dose-dependent killing of cancer cells that expressing high levels of EphA2 
receptor, including glioblastoma multiforme cells, as well as breast and prostate 
cancer cells [156].  An anti-EphA2 antibody, conjugated with the microtubule 
polymerization inhibitor monomethylauristatin phenylalanine (MMAF) has also 
been developed by MedImmune Inc. for targeted therapy.  The conjugated 
antibody significantly inhibits tumor cell growth both in vitro and in vivo without 
any observable adverse effects [157]. These findings make ephrinA1- or anti-
EphA2-based cytotoxins a potentially attractive therapeutic strategy for the 
treatment of breast cancer.  
 Small interfering RNAs (siRNAs) that specifically inhibit gene expression have 
rapidly become a powerful tool in both mechanistic studies and targeted 
therapeutics. It has been previously reported that siRNAs directed against EphA2 
resulted in decreased protein expression decreased tumor growth in a pancreatic 
cancer xenograft model [89].  More recently, siRNAs against EphA2 were 
incorporated into packaging liposomes composed of the neutral lipid 1,2-dioleoyl-
sn-glycero-3-phosphatidylcholine (DOPC) for efficient in vivo delivery.  Neutral 
liposome-coupled EphA2 siRNA reduced tumor growth in an orthotopic mouse 
model of ovarian cancer both in the presence and absence of paclitaxel [90, 
158], 
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suggesting the feasibility of siRNA as a clinically applicable therapeutic 
approach.  
 Eph receptors and ephrins have emerged as critical regulators of tumor 
angiogenesis, making them attractive targets for inhibition of neovascularization 
[1, 75].  More importantly, Eph/ephrin signaling provides a possible mechanism 
responsible for resistance to anti-VEGF therapy [104].  Soluble Eph receptors 
have been used to inhibit endogenous Eph receptor signaling in vascular 
endothelium and tumor angiogenesis in vivo [88, 110, 159, 160].  More recently, 
the Pasquale laboratory has developed a peptide, TNYL-RAW, which competes 
with ephrin-B2 for binding to EphB4 receptor [161, 162].  In addition, two isomeric 
small molecule compounds have been identified that selectively inhibit ephrin 
binding to EphA4 and EphA2 [16, 161].  Both the EphB4 blocking peptide and 
EphA2/EphA4 antagonistic compounds inhibit Eph receptor phosphorylation and 
capillary-like tube formation in human umbilical vein endothelial cells [16], 
suggesting that they can potentially serve as starting points to develop anti-
angiogenic therapies in cancer treatment. 
 In addition to being direct targets for therapeutic intervention, EphA2-derived 
peptides have been used in a dendritic cell-based vaccine for immunotherapy in 
glioblastoma multiform and colon cancer [163-165].  Early studies showed that in 
renal cell carcinoma, EphA2-derived peptides induced specific, tumor-reactive 
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Table 3. Eph-Ephrin Based Therapeutics (adapted from [166, 167]) 
Molecules/Treatment Target Tumor/Tissue 
Type 
Activity Reference 
Kinase Inhibitors EphB4 Angiogenic 
targets 
ATP Competition [168-170] 
Kinase Inhibitors Eph 
Receptors 
 ATP Competition [171-176] 
siRNA EphA2 Ovarian, 
Pancreatic 
mRNA downregulation [89, 90, 
177] 
oligonucleotides EphA2 Breast Protein downregulation [113] 
siRNA EphB4 Ovarian, 
Colon, 
Prostate, 
Bladder, 
Breast 
mRNA downregulation [84, 92, 
178-180] 
oligonucleotides EphB4 Prostate, 
Bladder, 
Breast, 
Ovarian 
Protein downregulation [84, 92, 
178, 179] 
EphA2-Fc and EphA3-
Fc 
EphrinA Pancreatic, 
Breast 
Eph Competition [88, 159, 
160, 181] 
sEphB4 EphrinB Head and 
Neck, Breast 
Eph Competition [182, 183] 
KYL peptides EphA4 Neurons Ephrin Competition [161, 184] 
SNEW peptides EphB2 Neurons Ephrin Competition [162, 185] 
TNYL-RAW peptides EphB4 Neurons Ephrin Competition [185-187] 
Dimethyl-pyrrole 
derivatives 
EphA2, 
EphA4 
 Ephrin Competition [161, 188] 
2H9 antagonistic 
mAb 
EphB2 Colon Ephrin Competition [189] 
Antibody Conjugates EphA2 Ovarian, 
Breast 
Eph Activation and 
Degradation 
[113, 154, 
157, 190-
192] 
Bispecific antibody EphA2  T cell 
recruitment/redirection 
[155] 
Adenoviral therapy EphA2 Pancreatic Transduction of EphA2 
Tumor Cells 
[193] 
EphrinA1 exotoxin EphA 
Receptors 
Brain Exotoxin Internalization [156] 
EphrinA1 Fc EphA 
Receptors 
Breast Eph 
Activation/Degradation 
[194] 
EphrinB2 Fc EphB4  Eph [109] 
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Activation/Degradation 
EphrinA1 Nanoshells EphA 
Receptors 
Prostate Photo-thermal ablation 
of tumor cells via 
absorption 
[195] 
64Cu-DOTA-1C1mAb EphA2 Colon, 
Prostate, 
Ovarian, 
Melanoma 
RadioimmunoPET [196] 
YSA-peptide-
magnetic 
nanoparticles 
EphA2 Ovarian, 
Leukemia 
Binding for cell capture [197, 198] 
111Indium-labeled 
antibody 
EphA3 Melanoma Binding for tumor 
detection 
[199] 
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CD8+ and CD4+ T cell responses.  The reactivity of CD8+ T cells to EphA2 
peptides was stronger in T cells isolated from post-surgery disease-free patients 
than from patients with active disease, suggesting that the immune system of 
cancer patients actively monitors EphA2-derived epitopes [163].  More recently, 
vaccination using dendritic cells pulsed with EphA2 peptides in a murine colon 
cancer model revealed that immunization inhibited the growth of MC38 tumors 
expressing EphA2, but did not have an effect on BL6 tumors that do not express 
EphA2 [164].  Furthermore, Hatano et al. reported that stimulation of peripheral 
blood mononuclear cells from glioma patients and control healthy donors with 
dendritic cells loaded with EphA2 peptide elicited an antigen specific cytotoxic T 
cell response [165].  These preliminary results demonstrate that EphA2-derived 
epitopes may represent important candidate vaccines to be tested in clinical trials 
for the treatment of malignant cancers. 
 
Conclusion 
 The field of Eph receptors and their interacting ligands (ephrins) is relatively 
young, having only been active for the past 20 years.  However, the field of Eph 
biology has grown immensely in recent years.  It has grown beyond the roles in 
normal physiology during embryonic development and axonal guidance to 
encompass propagating disease pathogenesis (e.g. tumorigenesis) and 
maintaining intricate cell communication signals between cells.  Research from 
our lab and others has greatly expanded the evidence implicating Eph and ephrin 
signaling in cancer and tumor progression while also expanding the known 
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functions of Eph receptors and their respective ligands.  As this knowledge has 
expanded, however, so has the complexity and paradoxical effects of Ephs and 
ephrins.  An example of this is demonstrated through multiple screening methods 
showing that while human cancers express multiple Ephs and/or ephrins, both 
increased and decreased expression can lead to tumorigenesis and/or tumor 
progression.  Furthermore, as demonstrated recently in elegant work by Bing 
Cheng Wang’s group the same signaling pathway can be modulated in the same 
cancer leading to different outcomes dependent on whether or not the ephrin 
ligand is present [37].  Consistent with this is the evidence generated confirming 
the ability of Eph receptors and ephrin ligands to both promote and inhibit 
tumorigenicity.  The molecular mechanisms that regulate these divergent 
functions, as well as the specific contexts under which tumor promoting versus 
tumor suppressive functions are selected, are still being studied and only now 
being brought to light. 
 Eph receptors are only now being seen as master regulators capable of 
propagating oncogenic signals or attenuating them.  This contrast is likely due to 
the ability of Eph receptors to signal in a bidirectional manner.  Furthermore we 
have recently learned of the ability of other proto-oncogenic receptor tyrosine 
kinases to cooperate with Eph and ephrin signaling to influence cancer cell 
activity.  The differences in spatial and temporal coordination of inputs, as 
expressed through proximity, may also result in the observed differences in Eph 
and ephrin signaling outcomes [200].  It is clear that a large number of cell-type-
dependent and context-dependent factors contribute to the multi-faceted role of 
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Eph receptor in cancer cells, tumor microenvironment and 
homeostasis/development.  As a result of this inherent complexity, Eph receptor-
based therapeutic strategies must be carefully evaluated before administration.  
In particular, therapies designed to either activate or block an Eph receptor may 
also alter the signaling function of the ligand in adjacent cells, due to bidirectional 
signaling of the Eph/ephrin system.  Further research in dissecting context-
dependent Eph receptor signaling is essential for developing successful 
therapeutic strategies for a reliable treatment against breast cancer.   
 
Purpose of this study 
 Although a great deal of information has been disseminated in regards to Eph 
receptors and ephrins in development and cancer, there still remains a great deal 
that is not understood such as:  Eph receptor function in crosstalk with oncogenic 
pathways, microenvironmental communication, tissue/context specific 
interactions leading to changes in signaling, as well as how the Eph system 
influences the metastatic cascade from tissue invasion to metastatic cell 
interactions at secondary sites of colonization.  This dissertation examines the 
function of EphA2 in normal mammary gland development to aid in 
understanding the balance of Eph function between normal and 
aberrant/oncogenic signaling.  This study demonstrates that EphA2 deficiency 
impairs mammary gland epithelial growth and branching through a RhoA-
dependent mechanism.  Understanding the role of EphA2 in normal mammary 
gland development, and knowing that metastatic breast cancer cells have high 
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levels of EphA2, the second portion of my thesis focuses on how metastatic cells 
communicate with bone cells.  We hypothesize high levels of EphA2 on breast 
cancer cells are able to interact with osteoclasts in the bone causing activation of 
these cells to induce osteolysis, a common effect seen clinically in aggressive 
breast cancer.  Together, these data demonstrate that EphA2 regulates several 
processes in tumor progression, including early tumor epithelial growth and 
invasion, as well as metastatic progression and pathogenesis in the bone 
microenvironment.  Thus, in elucidating these diverse roles in breast cancer, we 
have identified several points at which anti-EphA2 therapeutic antibody maybe 
an effective new therapy in the treatment of bone metastatic disease. 
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CHAPTER II 
 
Regulation of mammary gland branching morphogenesis by EphA2 
receptor tyrosine kinase 
 
The work presented in this chapter was published under the same name in the 
journal Molecular Biology of the Cell May, 2009 [69] 
 
Abstract 
 Eph receptor tyrosine kinases, including EphA2, are expressed in the 
mammary gland.  However, their role in mammary gland development remains 
poorly understood.  Using EphA2-deficient animals, we demonstrate for the first 
time that EphA2 receptor function is required for mammary epithelial growth and 
branching morphogenesis.  Loss of EphA2 decreased penetration of mammary 
epithelium into fat pad, reduced epithelial proliferation, and inhibited epithelial 
branching.  These defects appear to be intrinsic to loss of EphA2 in epithelium, 
as transplantation of EphA2-deficient mammary tissue into wild-type recipient 
stroma recapitulated these defects.  In addition, HGF-induced mammary 
epithelial branching morphogenesis was significantly reduced in EphA2-deficient 
cells relative to wild-type cells, which correlated with elevated basal RhoA 
activity.  Moreover, inhibition of ROCK kinase activity in EphA2-deficient 
mammary epithelium rescued branching defects in primary cell and organoid 
cultures.  These results suggest that EphA2 receptor acts as a positive regulator 
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in mammary gland development, functioning downstream of HGF to regulate 
branching through inhibition of RhoA.  Together, these data demonstrate a 
positive role for EphA2 during normal mammary epithelial proliferation and 
branching morphogenesis.  
 
Introduction 
 Mammary epithelial morphogenesis is a complex developmental process 
during which an extensive network of branched ducts forms from a rudimentary 
epithelial bud [reviewed in [64, 201]].  This process, termed branching 
morphogenesis, is most active during puberty.  In response to hormonal stimuli, 
terminal end buds (TEB) form at the tips of the ducts and invade into the 
surrounding stroma.  New primary ducts then form by bifurcation of the TEBs and 
secondary side-branches sprout laterally from the trailing ducts.  This process is 
reiterated through branching and tissue remodeling until the entire mammary fat 
pad is filled with a ductal tree in the virgin gland.  During pregnancy, the 
mammary epithelium undergoes differentiation and expands drastically to meet 
the demand of milk production throughout lactation.  After weaning, the 
mammary epithelium regresses through a process of programmed cell death. 
 Mammary gland branching morphogenesis is regulated by endocrine 
hormones and local paracrine interaction between the developing epithelial ducts 
and their adjacent mesenchymal stroma.  Although the mediators of the complex 
interaction in mammary gland development are not fully characterized, receptor 
tyrosine kinases (RTK) are among the critical regulators of branching 
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morphogenesis [57].  Hepatocyte growth factor/scatter factor (HGF/SF), a 
mesenchymal derived mitogen and morphogen, induces branching 
morphogenesis through its receptor c-Met, which is expressed on mammary 
epithelial cells [reviewed in [202, 203]].  More recently, expression of multiple 
Eph family RTKs has been reported in the mammary gland [reviewed in [204]].  
However, their role in branching morphogenesis remains to be investigated.  
 The Eph RTK family is the largest family of RTKs identified in the genome, 
with at least 15 receptors and 9 ligands identified in vertebrates [Reviewed in [75, 
184]]. The family is subdivided into class A and class B based on homology and 
binding affinity for two distinct types of membrane-anchored ephrin ligands.  
Class B receptors generally bind to class B ephrins that are attached to the cell 
membrane by a transmembrane-spanning domain, while A class receptors 
normally interact with glycosyl-phosphatidylinositol (GPI)-linked class A ephrins, 
although interclass binding does occur among certain family members [Reviewed 
in [205, 206]]. These molecules function in cell-cell communication during 
embryogenesis to regulate angiogenic remodeling processes, axon guidance, 
and tissue boundary formation [Reviewed in [18, 207]].  In adult organisms, 
members of this RTK family have been linked to tumor progression and 
neovascularization [Reviewed in [206]].  
 The first Eph receptors discovered in mammary gland are EphB4 (myk-1) and 
EphA2 (myk-2) [68].  The EphB4 receptor is expressed predominantly on 
myoepithelial cells surrounding the ducts and alveoli, whereas its cognate ligand, 
ephrin-B2, is expressed complementarily in luminal epithelial cells.  Expression of 
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both ligand and receptor is estrogen-dependent [65].  More recently, a genome-
wide transcript analysis identified EphA2 receptor and ephrin-B1 as the only two 
Eph molecules that are enriched in TEBs relative to ducts [67].  Functionally, 
overexpression of EphB4 in mammary epithelial cells in MMTV-EphB4 transgenic 
mice disrupts the patterning of the normal mammary ductal tree, induces 
angiogenesis, accelerates tumor formation, and promotes metastasis when co-
expressed with MMTV-Neu in bigenic mice [66].  EphA2 receptor overexpression 
has been associated with many types of cancer, including breast cancer 
[reviewed in [74, 75, 208]].  In addition, EphA2 has been shown to regulate HGF-
induced MDCK cell branching morphogenesis in three-dimensional collagen gels 
[53].  However, the role of EphA2 in mammary gland development remains 
unknown. 
   In this study we investigated the role of EphA2 in mammary gland branching 
morphogenesis in EphA2-deficient mice.  We found that loss of EphA2 inhibits 
the proliferation of the mammary epithelium and delays ductal branching 
necessary for complete fat pad filling.  At the cellular level, EphA2-deficiency 
resulted in marked reduction of branching in response to HGF stimulation.  This 
defect, at least in part, is due to misregulation of Rho family GTPase function.  
These results suggest that EphA2 is required for mammary gland branching 
morphogenesis in vivo.   Taken together, these data demonstrate a positive role 
for EphA2 in proliferation and branching morphogenesis of normal mammary 
epithelium. 
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Materials and Methods 
Animals: Animals were housed under pathogen-free conditions, and 
experiments were performed in accordance with AAALAC guidelines and with 
Vanderbilt University Institutional Animal Care and Use Committee approval. 
EphA2-deficient mice were backcrossed with FVB animals for 7 to 10 
generations prior to analysis.   Animals that were wild-type, heterozygous, or null 
for ephA2 [105, 106] were identified by polymerase chain reaction (PCR) 
analysis of genomic DNA from tail biopsy using the following primers: 5’-GGG 
TGC CAA AGT AGA ACT GCG-3’ (forward), 5’-GAC AGA ATA AAA CGC ACG 
GGT G-3’ (neo), 5’-TTC AGC CAA GCC TAT GTA GAA AGC-3’ (reverse).  
 
Reagents: Antibodies used include anti-EphA2 (SC-924 2 mg/ml, Santa Cruz 
Biotechnology; Santa Cruz, CA; 5 mg/ml, Zymed Laboratories, Burlingame, CA; 
D7 clone 2 mg/ml, Upstate Biotechnology, Lake Placid, NY), anti-Ephrin-A1 
(clone P1 1:200, Immunex, Seattle, WA), normal rabbit IgG (Santa Cruz 
Biotechnology), anti-b-tubulin (1:500, Sigma-Aldrich, St. Louis, MO), biotinylated 
anti-PCNA (1:500, BD Biosciences, San Jose, CA).  Avidin peroxidase (ABC) 
reagents were purchased from Molecular Probes (Eugene, OR). 4’,6-Diamidino-2 
phenylindole dihydrochloride (DAPI) was purchased from Sigma-Aldrich. Liquid 
3,3’-diaminobenzidine tetrahydrochloride (DAB) substrate kit was purchased from 
Zymed Laboratories.  Recombinant murine HGF was purchased from R&D 
Systems (Minneapolis, MN).  
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Whole Mount Mammary Gland Analyses: Whole-mount hematoxylin staining 
of mammary glands was performed by taking number 4 inguinal mammary glands 
and fixing in 10% buffered formalin (Fisher, SF93-4) overnight at 4°C.  The 
glands were washed in acetone, equilibrated into 100% ethanol, and stained in 
Mayer's hematoxylin solution (VWR Scientific, West Chester, PA) for one hour at 
room temperature, light protected.  Following staining the glands were destained 
in tap water and then further destained in 50% ethanol acidified with hydrochloric 
acid at a 0.05 M final concentration.  The glands were then dehydrated in a 
graded ethanol series followed by xylenes, and mounted on slides for 
photodocumentation. 
 
Proliferation, apoptosis, and immunohistochemistry assays: Proliferation 
and apoptosis in mammary gland in situ were assessed by PNCA 
immunohistochemistry or TUNEL analysis, as previously described [5].  For 
immunohistochemistry, sections were de-waxed, rehydrated, and subjected to 
thermal antigen retrieval in citrate buffer (2 mM citric acid, 10 mM sodium citrate, 
pH 6.0) using a PickCell Laboratories 2100 Retriever as per manufacturer’s 
instructions.  Sections were incubated with primary anti-EphA2 antibody (5 
mg/ml, Zymed Laboratories), anti-ephrin-A1 antibody (1:200, Immunex), or 
control rabbit IgG (5 mg/ml, Santa Cruz Biotechnology) overnight at 4 C, followed 
by 1 hour room temperature incubation with biotinylated anti-rabbit antibodies 
(BD Biosciences).  Sections were then treated incubated with avidin-peroxidase 
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(Vector Laboratories), followed by DAB substrate, counterstained with 
hematoxylin (Fisher Scientific) and mounted. 
 
Mammary Fat Pad Clearing and Transplantation: Fat pad clearing and 
transplantation of EphA2-deficient mammary tissue into wild-type hosts, as well 
as wild-type tissue into EphA2-deficient hosts, was performed as described 
previously [209].  Briefly, the endogenous epithelium was surgically removed 
from the right #4 inguinal mammary gland of 3-week old mice by excising the 
portion of the fat pad between the nipple and the lymph node, which contains the 
endogenous epithelium rudiment.  A small portion (approximately 2 mm2) of 
donor tissue from 6-week old female mammary glands was engrafted into the 
remaining fat pad.  Mammary glands harboring transplanted tissue were 
harvested 8 weeks post-transplantation and processed for whole-mount staining 
as described above.  Engraftment of exogenous mammary epithelium was 
verified by radial outgrowth of epithelium, versus glands contaminated with 
endogenous epithelium that grows directionally from the nipple toward the body 
cavity.   
 
Isolation and Culture of Primary Mammary Epithelial Cells: Primary mouse 
mammary epithelial cells (PMEC) were isolated from FVB wildtype and EphA2 
deficient FVB female mice and cultured as follows:  mammary glands were 
collected under sterile conditions and digested at 37°C for 4 h in 3 mg/ml 
collagenase A (Beohringer Mannheim #103578) in PBS (pH 7.4), 100 units/ml of 
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hyalurondidase (Sigma #H-4272), and 1:1000 dilution of Fungizone (Invitrogen 
#15290-018). The cell suspension was first plated on bacterial Petri dishes for 3 
to 5 hours to separate epithelial cells from fibroblasts, which adhere to Petri 
dishes. The epithelium-enriched cell suspension was then plated on dishes 
coated with collagen (Vitrogen) in 0.02N acetic acid washed with PBS before 
addition of cell culture media consisting of serum-free DMEM-F12 (50:50; Gibco 
BRL), 5 ng/ml estrogen (Sigma E-4389), 1 ng/ml progesterone (Sigma P-7556), 5 
ng/ml EGF (Sigma E-4127), and 5 mg/ml insulin (Sigma I-1882) and cultured at 
37°C in 5% CO2. 
 
In vitro branching morphogenesis assays:  HGF-induced branching of 
PMECs isolated from wild-type or EphA2-deficient female mice was scored in 
three-dimensional mammosphere culture using a modification of previously 
described methods [210].  Briefly, PMECs were trypsinized and 100,000 cells 
were plated on a thin layer of growth factor-reduced Matrigel (BD Biosciences) in 
8 well chamber slides (BD Falcon).  Cultures were maintained in normal PMEC 
media supplemented with 2% growth factor-reduced Matrigel and 5% FCS in the 
presence or absence of 20 ng/ml recombinant murine HGF (R&D Systems) for 5 
days, changing the media after 48 hours.  Cultures were photographed on day 5 
using an Olympus CK40 inverted microscope with digital camera, and branching 
was scored by counting branches in 4 independent 10X photographs per culture 
condition.  For some experiments, PMECs were infected with 108 pfu/ml 
recombinant adenoviruses harboring constitutively active RhoA (Q63L, Cell 
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Biolabs), EphA2, or control b-galactosidase [5] 24 hours prior to mammosphere 
culture.  For ROCK inhibition studies, PMECs were pre-treated with 0, 0.1 mM, 1 
mM, or 10 mM Y27632 ROCK inhibitor (Calbiochem) or vehicle control for 1 hour 
prior to mammosphere culture, and cultures were treated again after 48 hours for 
1 hour.  All experiments were performed three times with 4 independent cultures 
per condition in each experiment.  
 
Rho Kinase Assay:  Primary mammary epithelial cells were plated in 6 well 
plates and stimulated with HGF (25 ng/ml) for 15 minutes upon reaching ~60% 
confluency.  Cells were harvested in a 1.0% Triton X-100 lysis buffer consisting 
of 50mM Tris-HCl, pH 8.0, 1.0% Triton X-100, 1 mM PMSF, 5 µg/ml leupeptin, 2 
µg/ml aprotinin, and 1 mM sodium orthovanadate.  Harvested cells were 
sonicated and cleared lysates were assayed for ROCK activity using the CycLex 
Rho-Kinase Assay Kit (MBL Inc.) according to manufacturer’s protocol.  Briefly, 
10 µL of each sample was incubated with a substrate corresponding to the C 
terminus of recombinant Myosin Binding Subunit of myosin phosphatase (MBS). 
The phosphorylated form of threonine 696 of the MBS was detected by an HRP 
conjugated detection antibody AF20, coupled with TMB color reaction.  
Absorbance was measured at 450nm, which reflects relative amount of Rho-
kinase activity.  For some experiments, PMECs were infected with 108 pfu/ml 
recombinant adenoviruses harboring EphA2, or control b-galactosidase [5] 48 
hours prior the ROCK assay. 
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In Situ Rho/Rac Activity Detection Assays:  Detection of GTP-bound Rho and 
Rac in mammary gland sections was performed as described previously [211].  
Briefly, paraffin-embedded tumor sections were rehydrated, treated with 0.01% 
trypsin (Cellgro/Mediatech) for 5 minutes, and blocked for 30 minutes in M.O.M. 
dilutent (Molecular Probes).  Sections were incubated with purified Pak-1 binding 
domain-glutathione S-transferase (PBD-GST), Rhotekin binding domain GST 
(RBD-GST) fusion protein, or GST control in M.O.M. dilutent containing 10 mM 
MgCl2 for 15 minutes at room temperature.  Binding of GST fusion proteins was 
detected using an anti-GST antibody (Santa Cruz Biotechnology) followed by 
anti-rabbit Cy3.  Sections were counterstained with DAPI, photographed, and 
binding of GST fusion proteins quantified based on Cy3+ pixel area using NIH 
Image J software. 
Statistical Analyses:  Statistical analysis of developmental and in vitro studies 
were performed using 2-tailed, paired student’s T-tests.  For tumor studies, both 
T-tests and Chi square analyses were performed. 
 
Results 
Loss of EphA2 impairs normal development and architecture of the 
mammary epithelial tree.  We first assessed expression of EphA2 and its 
preferred ligand, ephrin-A1, in normal mammary gland tissue isolated from 6 
week old female mice.  We observed EphA2 expression on the surface of luminal 
epithelial cells, while the surrounding myoepithelium and stroma did not express 
detectable protein under our staining conditions (Fig. 9A).  We confirmed 
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specificity of staining, as well as loss of EphA2 expression in EphA2-deficient 
animals, by probing mammary gland tissue sections  (Fig. 9A) and mammary 
gland lysates (Fig. 9B) with anti-EphA2 antibodies.  EphrinA1 protein expression 
patterns were similar to those observed for EphA2, with protein detected on the 
surface of luminal epithelial cells (Fig. 9C).  These expression patterns are 
consistent with reported mRNA expression of EphA2 and ephrinA1 in luminal 
epithelial cells [67], suggesting that this receptor-ligand pair may regulate 
epithelial morphogenesis.    
 To determine the role of EphA2 in mammary gland morphogenesis, we 
performed whole mount analysis of mammary glands from EphA2-deficient mice 
and wild-type littermate controls following a time course.  In control animals, at 
the onset of puberty at approximately 3.5 weeks, the rudimentary mammary 
epithelium anlagen undergoes rapid proliferation and invades the stroma by 
directional growth and branching, giving rise to the characteristic mammary 
epithelial tree that populates the entire mammary fat pad at 10 weeks of age.  In 
contrast, the EphA2-deficient animals exhibit severe growth retardation (Fig. 10).  
This defect is more prominent at 5 and 6 weeks of age, with reduced branching 
activity and decreased numbers of TEBs (Fig. 10A-D). In addition, outgrowth of 
the mammary epithelial tree was also retarded in these animals (Fig. 10A & D).  
In mature animals at 12 weeks, approximately 50% of the EphA2-deficient 
animals exhibited a fully formed mammary ductal tree (Fig. 10D).  Failure of the 
mammary epithelium to fully penetrate the mammary fat pad persists in 
approximately 30% of these animals at 8 months [5].   
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 We did not observe any defects in expansion of the mammary epithelium 
during pregnancy, function during lactation, or in apoptosis during post-lactational 
involution in EphA2-deficient animals relative to controls (data not shown).  
To dissect cellular mechanisms responsible for defects in outgrowth and 
branching in EphA2-deficient mice, we compared proliferation and apoptosis of 
mammary epithelial cells in these and control animals.  Cell growth was 
assessed by quantifying expression of proliferating cell nuclear antigen (PCNA), 
a marker for actively dividing cells.  As shown in Fig. 11, high proliferative activity  
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Figure 19.  EphA2 receptor tyrosine kinase and ephrin-A1 ligand are 
expressed in luminal epithelial cells in virgin mammary gland tissue.  (A) 
Immunohistochemical staining in virgin mammary tissue sections prepared from 
wild-type (WT) 6-week old virgin female mice revealed EphA2 protein expression 
on the surface of luminal epithelial cells (arrowheads), but no apparent 
expression in myoepithelial cells/fibroblasts surrounding ducts (arrows) or in fatty 
tissue (*).  Staining specificity, as well as EphA2-deficiency, was confirmed by 
probing mammary tissue sections prepared from age-matched EphA2-deficient 
(KO) virgin female mice.  (B) EphA2 protein deficiency in KO mice versus WT 
was also confirmed by immunoblot analysis of protein lysates prepared from 
whole mammary gland tissue.  Uniform loading was confirmed by re-probing 
blots for expression of tubulin.  (C) We also observed expression of ephrin-A1, 
the primary ligand for EphA2 receptor, in luminal epithelial cells (arrowheads), 
versus surrounding stromal cells (arrows) and fat (*) in tissue sections prepared 
from 6-week old wild-type virgin female mice.  Staining specificity was validated 
by probing tissue with control rabbit IgG (rIgG).  Scale bars = 10 mm.    
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was observed in the mammary epithelium of 6 weeks old control wild-type mice.  
In contrast, cell proliferation was significantly reduced in EphA2-deficient 
littermates. We observed no significant difference in epithelial content and 
proliferation between control and EphA2-deficient mammary glands harvested 
from 12 week old mature female animals, indicating that mammary epithelial 
growth had recovered in EphA2-deficient animals (data not shown).  Nor did we 
detect any difference in the levels of apoptosis in mammary gland between 
EphA2-null animals and wild-type control littermates, either at 6 weeks or 12 
weeks of age (Fig. 11C). 
 
EphA2-deficiency inhibits HGF-induced mammary epithelial cell branching 
morphogenesis.   
Although we did not detect expression of EphA2 in the mammary gland stroma in 
tissue sections (Fig. 9A), lysates from primary mammary fibroblast cultures 
revealed low level EphA2 expression (data not shown).  Therefore, reduced 
mammary gland branching morphogenesis observed in EphA2-null animals could 
be due to either defects in mammary epithelial cells or the surrounding 
mesenchymal stroma. To distinguish the role of EphA2 in epithelium cells versus 
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Figure 10.  EphA2-deficiency impairs normal development and architecture 
of the mammary epithelial tree. (A) Whole-mount hematoxylin staining of 
number 4 inguinal mammary glands collected from WT and KO FVB female 
animals 5 and 6 weeks after birth.  Scale bar = 200 mm.  Quantification of 
numbers of terminal end buds (B) and branching points (C) in mammary gland 
whole mounts from 4-week and 5-week-old mice. (D) Mammary gland whole 
mounts prepared from KO EphA2 and WT EphA2 animals from 6 weeks of age 
and 12 weeks of age were analyzed for epithelial penetration into the fat pad by 
measuring the distance between the lymph node to the tips of the epithelial tree 
in gland.  Quantification of TEBs, branching points, and the degree of epithelial 
penetration through the mammary fat pad was performed by analyzing whole-
mount preparations from > 10 independent animals per developmental stage per 
genotype. Statistical analyses were performed using 2-tailed, paired student’s T-
tests.
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stroma, we performed reciprocal transplantation experiments in which we grafted 
EphA2-deficient mammary gland tissue into the cleared fat pad of wild-type 
female mice, as well as wild-type mammary gland tissue into the cleared fat pad 
of EphA2-deficient female mice.  Interestingly, we observed failed engraftment of 
EphA2-deficient mammary epithelium in 4 out of 10 animals, versus 1 out of 10 
animals engrafted with wild-type epithelium.  This observation is consistent with 
proliferation and outgrowth defects in endogenous EphA2-deficient epithelium 
(Figs. 10 and 11).  For animals in which the donor epithelium did engraft, we 
observed diminished branching in wild-type animals harboring EphA2-deficient 
epithelium, while wild-type epithelium grafted into EphA2-deficient animals 
displayed robust branching 8 weeks after engraftment (Fig. 12A).  These data 
suggest that the branching defects observed in EphA2-deficient animals are due 
to loss of EphA2 function in mammary epithelium versus stroma.   
To validate the data derived from reciprocal transplant experiments in an in vitro 
system where levels of specific branching morphogens may be manipulated, we 
isolated primary mammary epithelial cells (PMECs) from wild-type and EphA2-
deficient mice and tested their ability to branch and invade into matrix in a three-
dimensional basement membrane gel.  We did not observe any differences in 
low-level branching between wild-type and EphA2-deficient cells in untreated 
cultures.  A number of factors acting in a paracrine fashion are known to regulate 
mammary gland development via branching morphogenesis [212].  In particular, 
HGF promotes ductal outgrowth and tubule formation in the mammary gland 
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Figure 11.  EphA2 deficiency inhibits proliferation but has no effect on 
apoptosis.  (A) PCNA immunohistochemistry in mammary gland tissue sections 
from wild-type and EphA2-deficient animals.  Arrowheads indicate PCNA+ nuclei.  
Scale bars = 50 mm (B) Proliferation was assessed by quantification of nuclear 
staining for PCNA in tissue sections.  A significant reduction in the percentage of 
PCNA positive nuclei relative to total nuclei was observed in KO EphA2 
mammary glands, compared to WT controls (p<0.05).  (C) No significant change 
in the percentage of apoptotic nuclei, as assessed by TUNEL assay, was 
observed in KO mammary glands relative to WT controls.  Quantification of the 
percentage of PCNA+ or TUNEL+ nuclei was performed by analyzing > 10 
independent animals per developmental stage per genotype.  5 random 20X 
fields/tissue section were photographed for PCNA and TUNEL per each 
independent animal/genotype.  Statistical analyses were performed using 2-
tailed, paired student’s T-tests. 
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[202].  We thus analyzed the role of EphA2 in HGF-induced mammary epithelial 
cell branching morphogenesis.  As shown in Fig. 12, primary mammary epithelial 
cells form spheroid structures in growth factor reduced Matrigel, and EphA2-
deficient cultures display diminished branching relative to wild-type control cells.  
In response to HGF stimulation, wild-type spheroids undergo extensive 
remodeling and branching.  In contrast, EphA2-deficient spheroids fail to undergo 
branching morphogenesis, displaying significantly fewer branches relative to 
wild-type cells in response to HGF stimulation. Overexpression of wild-type 
EphA2 receptor in primary mammary epithelial cells via adenovirus transduction 
not only rescued phenotypes in EphA2-deficient cells, but also drastically 
enhanced branching morphogenesis in wild-type cells.  Taken together, these 
data suggest that EphA2 receptor is required for HGF-induced branching 
morphogenesis. 
 
Increased RhoA activity in EphA2-deficient cells inhibits mammary 
epithelial cell branching.   
We next investigated the molecular mechanisms through which EphA2 regulates 
mammary epithelial cell branching morphogenesis.  Dynamic regulation of the 
actin cytoskeleton is critical in a number of cellular processes including cell 
migration and branching morphogenesis.  RhoA GTPases are key regulators of 
actin stress fiber formation and are necessary for cell migration [213-215].   
Moreover, Ewald et al. recently reported that inhibition of ROCK kinase, a 
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Figure 12.  EphA2 activity is required in mammary epithelium for optimal 
branching in vivo, as well as for HGF-induced epithelial cell branching 
morphogenesis in Matrigel.  (A) To determine if defective epithelial branching 
in EphA2-deficient (KO) mice was due to loss of EphA2 function in epithelium 
versus stroma, we transplanted KO mammary tissue into the cleared fat pads of 
WT female mice, as well as WT mammary tissue into the cleared fat pads of KO 
female mice.  Photomicrographs display 2 independent wholemount preparations 
of mammary fat pads harboring transplanted tissue.  While WT epithelium 
displayed robust branching in KO stroma 8-weeks after transplantation, 
branching of KO epithelium was significantly diminished in WT hosts (p<0.05; 2-
tailed, paired student’s T-test).  Scale bar = 200 mm.  Quantification of branching 
was performed by analyzing whole-mount preparations from 5 independent 
transplants/condition.  (B) Primary mammary epithelial cells isolated from WT or 
KO animals were transduced with adenoviruses expressing EphA2 (Ad-EphA2) 
or control LacZ (Ad-LacZ) and plated on growth-factor reduced Matrigel with or 
without HGF for 5 days and photographed.  HGF enhances branching 
morphogenesis in WT, but not KO, mammary epithelial cells.  The defects in KO 
cells was rescued by re-expressing wild-type EphA2 receptor.  Scale bar = 25 
mm.  (C) Branching morphogenesis was quantified by counting the number of 
branches per photograph in 4 independent samples per culture condition in three 
independent experiments.  Statistical analyses were performed using 2-tailed, 
paired student’s T-tests. 
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downstream effector of RhoA, results in hyperbranched mammary epithelium in 
organoid cultures [216], suggesting that RhoA is crucial for proper branching 
morphogenesis in mammary epithelial development.   To investigate whether 
RhoA GTPase is involved in HGF/EphA2 induced branching of mammary 
epithelial cells, we measured ROCK kinase activity in wild-type and EphA2-
deficient mammary epithelium.  As shown in Fig. 13A, HGF stimulation of primary 
mammary epithelial cells for 15 minutes induced ROCK kinase activity in wild-
type cells.  Interestingly, the basal level of ROCK activity is markedly increased in 
EphA2-deficient cells, and this level does not change in response to HGF 
stimulation.  Experiments in which we restored expression of EphA2 with 
adenoviral infection EphA2-deficient cells rescued the phenotype by reducing 
ROCK activity to near wild-type levels, though levels of ROCK activity remained 
similar in wild-type cells upon adenoviral EphA2 overexpression (Fig. 13A).  To 
determine the level of active RhoA GTPase in vivo, we performed effector-
binding assays on mammary gland tissue sections in situ [211].  Consistent with 
results from ROCK assay in vitro, RhoA activity is markedly increased in EphA2-
deficient mammary gland epithelium in 6 week old mice, compared to that in wild-
type control littermates, as judged by GST-Rhotekin binding detected by anti-
GST antibodies (Fig. 13B).  As a balance of RhoA and other small Rho GTPases 
activities (such as Rac1 and Cdc42) often determines the biological outcome in 
branching morphogenesis, we assayed Rac1 and Cdc42 activity in situ using  
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Figure 13.  Increased RhoA activity in EphA2 deficient mammary epithelial 
cells.  (A) Rho kinase activity was measured by an immune-based kinase assay, 
as described in Materials and Methods.  Rho kinase activity was significantly 
increased in EphA2-deficient mammary epithelial cells (p<0.05; 2-tailed, paired 
student’s T-test).  Data are a representation of 3 independent experiments.  (B) 
Rho GTPase activities were analyzed in 6 week old mammary glands in situ by 
incubating tissue sections with GST-Rhotekin or GST-Pak for the detection of 
RhoA and Rac1/Cdc42 activities, respectively; followed by detection using a Cy3 
conjugated anti-GST antibody.   Scale bars = 50 mm.  Rho activity was quantified 
based on Cy3 positive pixel area using NIH image J software.  Quantification of 
Rho activity was performed in four 40X fields/section in tissue sections from three 
independent wild-type or EphA2-deficient mammary animals.  Statistical 
analyses were performed using 2-tailed, paired student’s T-tests. 
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GST-Pak proteins.  We did not detect any significant levels of Rac1 and Cdc42 
activities in the 6-week-old mammary gland sections (Fig. 13C).  
 To determine the functional relevance of RhoA activity in EphA2-mediated 
branching morphogenesis, we first examined HGF-induced branching of primary 
mammary epithelial cells in cells expressing control adenovirus LacZ versus 
adenovirus harboring constitutively active RhoA mutant (CA-Rho).  CA-RhoA 
significantly inhibited branching in wild-type cultures, and slightly reduced 
branching in EphA2-deficient cultures (Fig. 14A, B).  We also assessed 
branching in the presence or absence of Y27632, an inhibitor of ROCK kinase.  
Treatment with Y27632 rescued branching defects in EphA2-deficient cells in 
both the presence and absence of HGF (Fig. 16D).  HGF stimulation enhanced 
Y27632-mediated branching in wild-type cells in a dose-dependent manner (Fig. 
14E).  Interestingly, HGF did not affect Y27632-mediated branching in EphA2-
deficient cells.  As HGF-mediated branching is impaired in EphA2-deficient 
mammary epithelium (Fig. 14), and as the ROCK kinase inhibitor rescues the 
branching defects in EphA2-deficienct cells in either the presence or absence of 
HGF (Fig. 14E), these data support a model (Fig. 15) in which EphA2 functions 
downstream of HGF to regulate mammary epithelial branching through inhibition 
of RhoA. 
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Figure 14. EphA2-dependent branching morphogenesis is dependent on 
RhoA activity. (A) Primary mammary epithelial cells isolated from WT or KO 
animals were transduced with adenoviruses expressing a constitutively activated 
RhoA (CA-Rho) or control LacZ.  Cells were plated on growth-factor reduced 
Matrigel with 20 ng/ml HGF for 5 days and photographed.  Branching in KO LacZ 
control cells was significantly diminished relative to WT LacZ control cells in 
response to HGF (*p<0.05; 2-tailed, paired student’s T-test).  Expression of the 
Q63L RhoA inhibited HGF-induced branching morphogenesis in WT cells.  Scale 
bar = 25 mm.  (B) Branching morphogenesis was quantified by counting the 
number of branches per photograph in 4 independent samples per culture 
condition in three independent experiments.  Statistical analyses were performed 
using 2-tailed, paired student’s T-tests.  (C) Expression of wild-type EphA2, CA-
Rho, and b-galactosidase via adenovirus transduction was confirmed by 
immunoblot analysis.  (D) Branching was also assessed in WT and KO primary 
mammary epithelial cells in the presence or absence of 20 ng/ml HGF and upon 
treatment with the Rho kinase inhibitor 10 mM Y27632.  As observed previously, 
WT, but not KO, cells displayed elevated branching in response to HGF (p<0.05 
WT untreated versus WT + HGF).  Branching was elevated in both WT and KO 
cells in the presence of Y27632.  While the addition of HGF enhanced Y27632-
mediated branching in WT cells, adding HGF had no effect on Y27632-mediated 
branching in KO cells (p<0.05 WT versus WT Y27632 and WT Y27632 versus 
Y27632 + HGF; p<0.05 KO versus KO Y27632; 2-tailed, paired student’s T-
tests).  (E) The differential effects of HGF Rho-dependent branching for WT 
versus KO cells was confirmed by a dose response assay in which cultures were 
treated with 0, 0.1 mM, 1 mM, or 10 mM Y27632 in the presence or absence of 
HGF. 
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Discussion 
 Expression of several Eph receptor tyrosine kinases in mammary gland has 
been reported [204].  However, their role in mammary gland development 
remains poorly understood.  Using EphA2-null animals, we demonstrated for the 
first time that EphA2 receptor function is required for mammary gland branching 
morphogenesis.  Loss of EphA2 resulted in decreased penetration of mammary 
epithelial into the fat pad, reduced proliferation of epithelial cells, and inhibition of 
mammary epithelial branching.  In addition, HGF-induced mammary epithelial 
cell migration and branching morphogenesis was significantly reduced in EphA-
deficient cells, compared with that in wild-type cells.  These results suggest that 
EphA2 receptor acts as a positive regulator in mammary gland development. 
 Other studies, however, suggest that Eph receptors may inhibit mammary 
gland morphogenesis.  Overexpression of EphB4 in mammary epithelium under 
the control of MMTV promoter/enhancer led to less branching activity, reduced 
alveolar buds, and a decrease in proliferation of mammary epithelial cells [66].  
Although not observed in mammary epithelium, this phenotype is reminiscent of 
the effect of EphA receptor activation seen in MDCK cells in response to HGF-
induced branching morphogenesis in collagen gels [53].  In this model, co-
stimulation of MDCK cells with ephrinA1 and HGF inhibited sprouting and 
induced the collapse of pre-existing branches.  These results suggest that high 
levels of Eph receptor signaling above the endogenous level in epithelial  
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Figure 16:  Model for HGF-mediated regulation of EphA2 in mammary 
epithelial branching morphogenesis.   HGF produced by mesenchymal cells 
within mammary stroma binds to c-Met receptor, expressed on mammary 
epithelium.  Through activation of EphA2 receptor function by an as yet 
unidentified mechanism, Rho activity is then downregulated to promote 
branching morphogenesis of the developing mammary epithelium during puberty. 
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cells, either by overexpression of receptor or exogenous stimulation with a large 
dose of ephrin ligand, may inhibit branching morphogenesis.  However, low 
levels of endogenous EphA2 receptor are required for proper mammary gland 
development in vivo based on our data.  
 Epithelial branching morphogenesis is a fundamental biological process 
underlying the development of many organs.  In breast tissue, epithelial 
branching morphogenesis is driven by endocrine hormonal stimuli that elicit local 
paracrine interactions between the developing epithelial ducts and their adjacent 
mesenchymal stroma.  Cytokines and growth factors, such as HGF, FGF, TGF-ß, 
and amphiregulin are among molecules that are critical in local regulation of 
branching morphogenesis [57, 202, 217].  A common pathway activated 
downstream of these signaling molecules is the Rho family of small GTPases.  
These proteins cycle between an inactive, GDP-bound state and an active, GTP-
bound state, regulated by guanine nucleotide exchange factors (GEFs) that 
exchange GDP for GTP and GTPase activating proteins (GAPs) that promote 
hydrolysis of GTP to GDP [213, 214].  Recently, RhoA, Rac-1, and Cdc42 
GTPases have emerged as critical mediators of Eph signal transduction, as 
association of several Eph RTK family members with GEFs concomitant with 
activation of Rho family GTPases has been observed in a variety of cell types. 
Interactions between Eph RTKs and the GEFs ephexin, intersectin, and kalarin 
link Eph-mediated activation of Rho family GTPases to growth-cone collapse 
(ephexin) or dendritic spine morphogenesis (intersectin and kalarin) in neuronal 
patterning during embryogenesis [Reviewed in [18, 184, 206]].  More recently, 
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Eph signaling through Rho family GTPases has been linked to vascular 
remodeling and angiogenesis [106, 107].   In MDCK epithelial cells, Miao et al 
reported that ephrinA1 has no effect on RhoA but inhibits Rac1 activation 
induced by HGF in MDCK cells [53].  Here we show that EphA2-dependent RhoA 
activity modulates HGF-induced branching morphogenesis in mammary epithelial 
cells.  First, loss of EphA2 led to a constitutive higher level of RhoA GTPase 
activity, which is insensitive to HGF stimulation (Fig. 13A&B).  Interestingly, Rac1 
activity did not appear to be significantly altered in EphA2-deficient mice, 
indicating that RhoA activity is a primary target regulated by the EphA2 receptor 
(Fig. 13C).  Furthermore, a ROCK kinase inhibitor, Y27632, rescued branching 
defects in EphA2-deficient cells, (Fig. 14) functionally linking EphA2-dependent 
RhoA activity branching morphogenesis.  
 Regulation of Rho GTPase in mammary epithelium is complex.  For example, 
targeted disruption of p190-B RhoGAP inhibits mammary epithelial ductal 
outgrowth, and heterozygous female mice display reduced proliferation within 
TEBs and delayed outgrowth of mammary ducts [218].  As deletion of this GAP, 
which negatively regulates Rho, results in elevated Rho activity, these data are 
consistent with our findings that elevated RhoA function in virgin mammary 
epithelium is associated with decreased proliferation and ductal outgrowth in 
EphA2-deficient mammary epithelium.  Interestingly, overexpression of the same 
RhoGAP in mammary epithelium elevates branching in transgenic animals, 
though ductal elongation is still delayed [219].  These data suggest that 
disruption of Rho activity in mammary epithelium, either positive or negative, has 
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a profound impact on epithelial morphogenesis in vivo.  This hypothesis is 
consistent with the apparent differential regulation of Rho by EphA2 signaling in 
normal versus transformed mammary epithelium, which is influenced by 
cooperative signaling pathways.  In the present study, loss of EphA2 results in 
elevated RhoA activity in mammary epithelium that is accompanied by 
suppression of ductal outgrowth in vivo.  Moreover, impaired HGF-mediated 
branching in primary mammary epithelial cells and organoid cultures derived 
from EphA2-deficient mice is rescued by inhibition of the downstream effector 
ROCK in vitro.  These data are consistent with reported hyperbranching of 
mammary epithelial organoid cultures upon treatment with the same ROCK 
inhibitor [216].  In the normal mammary development, EphA2 may serve to 
restrict levels of active RhoA, enabling HGF to maintain levels of activity that 
promote the proper balance between branching and ductal outgrowth necessary 
for normal epithelial morphogenesis.  By contrast, elevated EphA2 expression in 
normal mammary epithelial cells via adenoviral transduction enhances 
branching. These data are consistent with reports that EphA2 overexpression in 
non-transformed MCF10A cells confers malignant transformation and tumor 
forming potential in vivo [71, 113], and overexpression in 4T1 mouse mammary 
adenocarcinoma cells enhances tumor progression and metastasis in vivo [11].  
In MMTV-Neu mice, loss of EphA2 diminishes tumorigenesis and metastasis, as 
well as reducing levels of active RhoA [5].  Thus, overexpression of EphA2, as 
well as cooperation with other oncogenic pathways in the context of mammary 
epithelial neoplasia, appears to enhances RhoA.   
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Interestingly, we did observe diminished RhoA activity in EphA2-deficient 
mammary epithelium relative to wild-type controls in 5 week old mice (data not 
shown), during which time the epithelium is still actively growing and branching.  
This observation suggests that EphA2 might also regulate Rho activity 
differentially at different stages of mammary epithelial development and/or 
malignant progression. For example, in normal mammary epithelial cells, ephrin-
A ligands, such as ephrinA1, may engage EphA2 receptors on adjacent cells and 
disrupt activation of Rho GTPase, thus alleviating inhibition of epithelial 
branching morphogenesis.  We previously reported that EphA2 physically and 
functionally interacts with ErbB2 and that co-expression of ErbB2 was sufficient 
to induce phosphorylation of EphA2 in the absence of exogenous ephrinA1 
ligand.  Moreover, EphA2-deficiency results in impaired Rho activation in MMTV-
Neu tumors and diminished motility of primary tumor cells [5].  Cell motility in 
EphA2-deficient MMTV-Neu tumor cells was rescued by overexpression of 
activated RhoA.  Thus, EphA2 receptor activation by ErbB2 and/or other receptor 
tyrosine kinases might enhance Rho activity, cell motility, and malignancy in the 
context of cancer cells in which weakened cell-cell contacts could impair 
interaction between EphA2 and endogenous ligands.  This might also be true in 5 
week old mammary glands, in which active growth might also diminish cell-cell 
contact and interaction between EphA2 and ephrinA1 on adjacent luminal 
epithelial cells.   It will be of great interest to investigate differential regulation of 
Rho family GTPases by EphA2 in normal mammary epithelium versus mammary 
adenocarcinoma. 
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 In conclusion, we provide the first evidence for EphA2 receptor regulation of 
normal growth and branching morphogenesis in normal mammary epithelial 
development.  Based on reciprocal transplantation and organoid culture studies, 
EphA2 function specifically in mammary epithelium, rather than mesenchymal 
stroma, appears to mediate these processes.  Our data suggest that EphA2 
receptor functions downstream of HGF to regulate mammary epithelial branching 
through inhibition of RhoA GTPase.
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CHAPTER III 
 
REGULATION OF TUMOR INDUCED OSTEOLYSIS BY RECEPTOR 
TYROSINE KINASE EPHA2  
 
 
Abstract 
Eph receptor tyrosine kinases are membrane bound receptors often expressed in 
human cancers.  Of the many Eph receptors, EphA2 is highly expressed in 
breast tumor cells and correlates with poor patient prognosis.  As metastasis of 
breast cancer to bone is a major cause of morbidity and mortality in patients, we 
investigated the role of EphA2 in this clinically relevant phenomenon.  Analysis of 
human breast-to-bone metastasis samples revealed EphA2 positive staining on 
tumor cells in close proximity to osteoclast at the tumor-bone interface.  To define 
the role of EphA2 in tumor cell-host bone cell interactions, mouse tibias were 
injected with osteolytic breast tumor cells lacking EphA2 activity.  Our data 
showed that inhibition of EphA2 activity significantly decreased tumor-induced 
osteolysis compared to controls.  Further in vitro analysis revealed that blocking 
EphA2 function resulted in defective precursor maturation into functional 
osteoclasts.  A human antibody targeted against EphA2, decreased breast tumor 
induced osteolysis in vivo.  In summary, we propose that EphA2 regulates cell-
cell interactions between tumor cells and bone cells via physical and indirect 
communication with osteoclasts.  Our studies indicate the selective inhibition of 
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EphA2 at the tumor-bone interface may be a benefit for the treatment of breast-
to-bone metastases.  
 
Introduction  
Metastasis to bone is a common occurrence among late stage breast 
cancer patients [114].  Bone metastases arising from primary breast cancers are 
predominately osteolytic in nature and cause skeletal complications including 
fractures, nerve compression, bone pain, and hypercalcemia [118, 220].  The 
establishment and growth of these metastases depends on the interaction 
between tumor cells and the host microenvironment.  The metastatic cells are 
able to seize control of normal bone remodeling processes to induce aberrant 
activation of osteoclasts leading to an increase in lysis of the bone [114, 220].  
Elevated osteoclast activity induces release of growth factors sequestered in the 
bone matrix such as transforming growth factor  (TGF- ), calcium, fibroblast 
growth factor (FGF) and insulin like growth factors (IGF).  These growth factors in 
turn promote tumor cell survival and growth in the bone microenvironment.  
Subsequent release of factors from the tumor cells like PTHrP (parathyroid 
hormone related protein), IL-1 (interleukin 1) and IL-8 (interleukin 8) can feed 
back to osteoblasts causing release of RANKL (receptor and activator of nuclear 
factor  B ligand) and further activating osteoclasts thereby completing the 
“vicious cycle” of tumor induced osteolysis [114].  A critical component in tumor-
induced osteolysis is the osteoclasts, large multinucleated differentiated cells 
with the unique ability to resorb mineralized bone [130].  Understanding the 
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mechanisms behind osteoclasts recruitment, maturation, and activation is key for 
developing new therapies to target osteolytic lesions resulting from breast cancer 
metastasis to the bone, which are often resistant to current therapies 
 Ephrin ligands and their receptors (Eph) belong to the largest family of 
receptor tyrosine kinases.  The Eph family of receptors and ligands plays critical 
roles in neuronal, vascular, and intestinal development as well as cellular 
migration and bone morphogenesis [70, 143].  Both ephrin ligands and Eph 
receptors are membrane bound proteins, which signal via cell-cell contact in both 
the receptor and ligand expressing cells (bidirectional signaling).  The family is 
subdivided into two subclasses based on sequence homology, binding affinity, 
and structure of the ephrin ligand.  The A-subclass of receptors (EphA1-EphA10) 
bind to the ligands tethered to the cell membrane by a glycosylphosphatidlinositol 
(GPI) anchor (ephrinA1-ephrinA6), while the B-subclass (EphB1-EphB4, EphB6) 
bind to ligands containing a transmembrane domain followed by a short 
cytoplasmic region (ephrinB1-ephrinB3).  The importance of signaling by both the 
receptor and ligand has been confirmed in multiple studies investigating 
angiogenesis, tissue boundary formation, cell sorting, and axonal guidance [221].   
 Recent studies demonstrated that bidirectional signaling by Eph-ephrin 
molecules plays an important role in bone biology.  EphrinB2 expression on 
osteoclasts inhibits osteoclast differentiation.  In contrast EphB4 expression on 
osteoblasts promotes differentiation [143].  This finding compliments the 
observed requirement for ephrinB1 ligand in the patterning of the developing 
skeleton [138, 139].  Class A Eph receptors have also recently been implicated in 
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bone homeostasis.  Irie et. al. reported that ephrinA2-EphA2-mediated interaction 
between osteoclast precursors and osteoblasts enhances osteoclastogenesis 
while inhibiting osteoblast differentiation [145].  Likewise, other studies have 
implicated A class receptors in giant cell tumors [148], and prostate cancer 
metastasis to bone [147, 149].  Although Ephs have been studied in normal bone 
homeostasis, the role of tumor induced-osteolysis remains unclear.  Here we 
demonstrate that breast cancer cell expression of EphA2 promotes osteoclast 
activation and development of osteolytic bone disease in a tumor context.  
Moreover, targeting EphA2 with a therapeutic, activating antibody that reduces 
cell surface expression and function significantly impaired breast tumor cell 
growth and osteolysis in vivo.  These data provide a strong rationale for 
development and application of molecularly targeted therapies against EphA2 for 
the treatment of breast cancer bone metastatic disease.   
  
Materials and Methods 
Reagents. All experiments involving animals were performed in accordance with 
AAALAC guidelines and with Vanderbilt University Institutional Animal Care and 
Use Committee approval.  4T1 C cells were previously generated [11].  All 
reagents were obtained from Sigma Aldrich unless otherwise noted. 
 
Intratibial injection. 4T1 WT and 4T1 C tumor cells (106) in a 50 L volume of 
sterile PBS were injected into the left tibia of deeply anesthetized Balb/c animals 
of 6-8 weeks of age. The contralateral tibia was injected with 50 L volume of 
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PBS alone and treated as the sham-injected control.  Mice were sacrificed 10 
days post surgery, and both the tumor-injected and contralateral tibias were 
collected for histological analysis. Similarly, the same number/volume of MDA-
MB-231 cells were injected into anesthetized immunocompromised 6 week old 
nude female mice (Harlan Sprague Dawley).  Tibias from both the tumor injected 
and sham contralateral legs were also harvested for analysis at 2 months post 
implantation.  All animal studies were repeated at least twice for a total of 8 
animals per condition.   
 
Treatment with therapeutic anti-EphA2 antibody.  Beginning 72 hours prior to 
tumor cell injection, recipient mice received intraperitoneal injections of 3F2-3M 
anti-EphA2 antibody (MedImmune/Astra Zeneca) or control IgG (10 mg/kg every 
72 hours for 8 weeks), prior to collection and analysis of hindlimbs.  At least 8 
animals/condition were analyzed in 2 independent experiments 
 
Histology.  TRAP staining: tumor and sham injected tibias were fixed for 4 hours 
in fresh 4% paraformaldehyde and decalcified for 3 weeks in 14% EDTA at pH 
7.4 with changes of solution every two to three days.  Tissues were embedded in 
paraffin, and 5 m sections were prepared for staining. For tartrate-resistant acid 
phosphatase (TRAP) staining the following technique was used.  Sections were 
rehydrated through a series of ethanols and then rinsed in PBS.  Following 
deparaffinization, histological samples were placed in warm incubation buffer 
(acetate buffer with tartaric acid pH 4.9) supplemented with a napthol AS-Bl 
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phosphate in ether substrate.  After incubation of slides for 30 minutes at 42 C, 
freshly prepared sodium nitrite solution was mixed with pararonsaniline dye stock 
in basic incubation solution to produce color after 10 minutes at room 
temperature.  Harris’s acid hematoxylin was used for counterstain. 
EphA2 staining.  Immunohistochemical detection of EphA2 in paraffin sections 
from collected hindlimbs was performed as described previously [69] using a 
rabbit polyclonal antibody (Zymed Laboratories, 5 μg/ml, overnight at 4°C).  
Antigen retrieval was performed by heating in a Pickcell 2100 retriever in the 
presence of citrate buffer (2 mM citric acid, 10 mM sodium citrate buffer, pH 6.0). 
Sections were washed in PBS and incubated with primary antibody overnight, 
followed by biotinylated anti-rabbit IgG secondary antibody (1:200; Transduction 
Laboratories, BD Biosciences PharMingen) for 1 h at room temperature.  Specific 
staining was detected using avidin-peroxidase (ABC kit, Vector Laboratories, 
Burlingame, CA) followed by 3,3' Diaminobenzidine (DAB) substrate (Zymed 
Laboratories).  Sections were counterstained with hematoxylin.  
 
Micro-computed tomography and histomorphometry.  Micro computer 
tomography (µCT) scanning (Concorde) of osteolytic lesions using segmentation 
analysis (Amira) were performed at week 8 post-transplantation. Animals were 
sacrificed at week 8 based upon µCT scan analysis.  After sacrifice, the samples 
fixed for 4 hours in fresh 4% paraformaldehyde and decalcified for 3 weeks in 
14% EDTA at pH 7.4 with changes of solution every two to three days.  Tissues 
were embedded in paraffin, and 5 m sections were prepared for staining.  
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Histomorphometry was calculated by using 2 non-serial sections of tumor 
bearing limbs stained with H and E to assess BV/TV and/or with TRAP to provide 
osteoclast number per millimeter of bone at the tumor bone interface. 
 
Bone marrow cell isolation.  Bone marrow cells were isolated from FVB mice 
and were cultured for three days in -minimal essential medium ( MEM) 
containing 10% fetal bovine serum and 10ng/ml of recombinant MCSF 
(Peprotech).  Following, three days of culture non-adherent cells were removed 
via PBS wash leaving adherent primary bone marrow cells.  These primary cells 
were further differentiated to osteoclasts by continued culture with 10ng/ml of 
MSCF and 50ng/ml of RANKL (Peprotech).     
 
Co-culture.  Raw264.7cells or primary bone marrow cells were plated on the 
bottom of a 6 well transwell plates in -MEM with the insert containing either 
osteoblasts (MC3T3.E1#4) tumor cells (4T1 WT or 4T1 C) with and without 
EphA2 function respectively, or a combination of the osteoblasts with tumor cells.  
TRAP assays were performed to detect activated osteoclasts in vitro according to 
manufacturer’s instructions  
 
Results 
EphA2 activity promotes breast cancer induced osteolysis 
 To determine if high levels of EphA2 could dysregulate bone remodeling and 
contribute to breast cancer bone, we expressed a cytoplasmic deletion mutant of 
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EphA2 (EphA2 C) in 4T1 mammary adenocarcinoma cells.  The EphA2 C 
mutant was able to inhibit endogenous wildtype EphA2 signaling in a dominant 
negative fashion [11].  4T1 breast cancer cells expressing either wildtype EphA2 
or EphA2 C were injected into the tibia of recipient mice to determine the effect 
of EphA2 in breast cancer induced osteolysis.  Balb/c mice injected with wildtype 
EphA2 4T1 cells demonstrated high levels of breast cancer induced osteolysis as 
observed by the absence of bone in microCT scans compared to those injected 
with 4T1 C (Figure 16A).  Tibias collected from animals injected with these 
breast cancer cells were decalcified and processed for paraffin embedding and 
histomorphometry analysis.  Tartrate resistant acid phosphatase (TRAP) 
combined with hematoxylin and eosin (H and E) staining revealed less bone in 
the parental injected samples in contrast to the 4T1 C though both demonstrated 
a high degree of tumor growth within the tibia (Figure 16B).  Quantification of 
total bone versus total volume (BV/TV) revealed four times less bone in the 
wildtype EphA2 4T1 injected animals than the 4T1 C injected animals as a 
percentage of  
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Figure 16.  EphA2 activity promotes breast cancer induced osteolysis in 
the intratibial bone metastasis bone model.  A) Live animal imaging 
reconstruction of CT scans demonstrating greater osteolysis in animals injected 
with wildtype EphA2 4T1 cells versus animals injected with 4T1 C cells.  B) 
Representative TRAP staining of sections from animals injected with wildtype 
EphA2 or EphA2 C 4T1 tumor cells.  Black arrows denote osteoclast resorbing 
bone.  C)  Quantifications of stained sections show a drastic decrease in bone 
volume versus total volume ratio (BV/TV) in the wildtype EphA2 4T1 cells relative 
to the 4T1 C cells (p=0.09).  D) Quantifications of the number of osteoclasts in 
these sections also revealed a greater number of osteoclasts in the 4T1 wildtype 
EphA2 cells relative to 4T1 C (p=0.15).  
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bone remaining (Figure 16C).  When paraffin embedded sections were stained 
for TRAP to detect osteoclasts, those animals injected with wildtype EphA2 4T1 
cells had three times more osteoclasts than 4T1 C or needle punch controls 
(Figure 16C).  
 Since 4T1 is a murine mammary tumor line, we tested whether EphA2 also 
plays a critical role in human breast cancer cells.  EphA2 activity was depleted in 
human MDA-MB-231 breast cancer cells, which express high endogenous 
EphA2 levels via a lentiviral delivered shRNA against EphA2.  We confirmed 
stable knockdown by immunoblotting and TAQMAN qRT-PCR analysis (Figure 
17 A and B respectively).  Proliferative and apoptosis studies of EphA2 
knockdown MDA-MB-231 cells revealed no significant differences in growth or 
death between knockdown and vector controls (Figure 17 C and D respectively).  
BrdU assays revealed a modest decrease in proliferation for tumor cells with 
decreased EphA2 expression similar to what was observed with the 4T1 C cell 
line [11].  TUNEL assays measuring apoptosis showed no differences in 
apoptosis in vitro upon loss of EphA2 also similar to what is recorded in the 
literature [11].   
 Utilizing the intratibial model for bone metastasis in mice, we investigated the 
role of EphA2 in mediating tumor cell-bone cell interactions in vivo in human 
breast cancer.  We injected MDA-MB-231 vector control cells and MDA-MB-231 
EphA2 KD cells via the tibia and monitored for development of tumors and 
lesions.  Following approximately 6 weeks, the hindlimbs were collected and 
analyzed.  With respect to tumor-induced osteolysis, the ratio of bone volume 
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(BV) versus total volume (TV) by microCt showed tumor-injected tibias with 
vector control MDA-MB-231 cells displayed more osteolysis than those injected 
with MDA-MB-231 EphA2 KD  (Figure 18A).  Bone histomorphometry on sections 
from these animals revealed greatly more osteoclasts in vector controls versus 
EphA2 KD cells as measured by TRAP staining.  Moreover, vector controls cells 
also displayed reduced volume of bone relative to EphA2 KD cells (Figure 18B).  
Similar differences in bone volume (BV) versus total volume (TV) that were 
originally seen in the microCt analysis were also seen upon analysis of these 
bone sections.  Furthermore, the faxitron images revealed larger areas of 
osteolysis in the vector control cells versus the MDA-MB-231 EphA2 KD cells 
(Figure 18C).  These data suggest tumor cell EphA2 is able to promote breast 
cancer induced osteolysis in both mouse and human breast cancers.  
 
EphA2 depletion inhibits tumor cell induced osteoclast differentiation 
 Numerous studies suggest tumor cell-bone cell interactions drive the vicious 
cycle that often induces osteolysis of the bone in breast cancer metastasis 
through increased activity of osteoclast function [222, 223].  Using a modified co-
culture model we investigated the ability of tumor cell EphA2 to induce osteoclast 
differentiation with or without osteoblasts as measured by TRAP staining.  In this 
assay primary bone marrow cells were plated underneath a transwell insert that 
was seeded with 4T1 tumor cells (wildtype EphA2 or EphA2 C) in the presence 
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Figure 17.  EphA2 knockdown in osteolytic breast cancer cells.  A) Using 
lentiviral vectors, stable knockdowns for EphA2 were made in MDA-MB-231 
breast cancer cells as shown by immunoblot.  B) Further, analysis of knockdown 
of EphA2 was confirmed via realtime PCR using a Taqman assay for EphA2.  
Loss of EphA2 does not have a statistically significant effect on proliferation (C) 
or apoptosis in vitro (D).  *p<0.05 n.s. not signifcant 
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or absence of osteoblasts to determine the ability of EphA2 to influence 
osteoclast differentiation (Figure 19A).  Primary bone marrow cells cultured in the 
presence of tumor cells with C expression had a reduced percentage of TRAP 
positive osteoclasts compared to wildtype EphA2 expressing cells (Figure 19B).  
Mature osteoblasts were also added to the tumor cells to see if physical 
interactions between the tumor cells and osteoblasts further induced the ability of 
osteoclast precursor cells to differentiate.  We observed a minimal increase in 
percentage of TRAP positive osteoclasts when tumor cells and osteoblasts were 
cultured together versus tumor cells cultured without any osteoblasts.  Though 
there was not a significant increase in percentage of TRAP positive osteoclasts 
when tumor cells were cultured with osteoblasts, the difference in percentage of 
osteoclast precursors that differentiated into TRAP positive osteoclasts was also 
reduced in the 4T1 C cells versus 4T1 wildtype EphA2 cells (Figure 19B).  
Human breast cancer cells plated in the aforementioned co-culture assay 
revealed a similar effect as the 4T1 murine breast cancer model.  MDA-MB-231 
vector control cells and MDA-MB-231 EphA2 KD cells seeded in the insert of a 
transwell filter with Raw267.4 cells, a mouse monocyte cell line, or primary 
mouse bone marrow cells underneath the insert enabled analysis of EphA2 on 
osteoclast differentiation (Figure 19C and D).  Following five days of culture, cells 
plated in the lower chamber of the transwells were fixed and stained for TRAP to 
mark osteoclasts that differentiated from the precursor cells.  EphA2 knockdown 
cells plated with RAW264.7 cells or with primary bone marrow cells significantly 
reduced the percentage of cells that differentiated into osteoclast relative to 
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vector controls (Figure 19C and D).  These results suggest EphA2 is able to 
mediate osteoclast differentiation induced by breast cancer cells likely through 
regulation of soluble factors. 
 
Osteoclast differentiation factors regulated by EphA2 
 Conditioned media collected from tumor cells in which EphA2 expression was 
diminished reduced the ability of osteoclast precursors to differentiate relative to 
vector control cells.  Based on these data, we hypothesized that an EphA2 
regulated soluble factor was responsible for tumor induced osteoclast 
differentiation.  Using a RayBiotech mouse cytokine array we analyzed 
conditioned media from each condition in Figure 21 using the 4T1 wildtype 
EphA2 and 4T1∆C cell lines.  Several cytokines, chemokines, and growth factors 
displayed changes in expression level greater than two fold (Table 4).  Many of 
these factors play important roles in bone biology including IL-6.  Quantitative 
RT-PCR revealed decreases in IL-6 levels in 4T1 C cells.  Similarly, MDA-MB-
231 vector control cells had higher levels of IL-6 versus MDA-MB-231 EphA2 KD 
cells (Figure 22A).  A human IL-6 ELISA assay was also performed on 
conditioned media collected from the MDA-MB-231 vector control cells and MDA-
MB-231 EphA2 KD.  We also observed a significant decrease in soluble IL-6 
levels for MDA-MB-231 EphA2 KD cells versus MDA-MB-231 vector control cells 
(Figure 22B).  Remarkably, further studies into important factors of bone  
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Figure 18.  Tumor mediated osteolysis is attenuated by loss of EphA2.  A) 
µCT scans of trabecular bone from animals injected with MDA-MB-231 tumor 
cells with EphA2 or knockdown cells of EphA2.  BV/TV ratios were calculated 
and displayed to the right.  B) Representative photomicrographs of histology from 
TRAP staining of EphA2 knockdown versus vector control cells displaying fewer 
osteoclast and more trabecular bone in the EphA2 knockdown tibia compared to 
the tibia injected with vector control breast cancer cells.  White arrowheads 
indicate trabecular bone and black arrowheads indicate TRAP positive 
osteoclast.  BV/TV quantification is displayed on the right.  C) Faxitron imagining 
of EphA2 knockdown tumor cells and vector control tumor cells injected into 
animals.  White arrowheads denote areas of osteolyssis and bone resorption 
seen more often in the vector control animals versus the EphA2 knockdown cells.   
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Figure 19.  Loss of EphA2 activity inhibits differentiation of osteoclast 
precursors.  A) Model for a modified co-culture assay used for analysis of tumor 
cell expressed EphA2 on differentiatin of osteoclast precursors in the presence or 
absence of mature osteoblasts.  B) Percentage of differentiated osteoclast in 4T1 
co-culture as measured by TRAP staining.  C) Percentage of differentiated 
osteoclast from MDA-MB-231 co-culture with Raw 267.4 as osteoclast precursor 
cell following five days in culture.  D) Quantification of differentiated osteoclasts 
from primary bone marrow cells following five days in culture after initial 3 day 
MCSF differentiation in MDA-Mb-231 co-culture.  Data presented as percentage 
of total. *p<0.05.  
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Table 4.  Mouse cytokine array targets.  Array was incubated with conditioned 
media from 4T1 WT EphA2 or 4T1∆C co-cultured with or without osteoblasts.  
Targets that had a 2 fold difference between WT EphA2 and ∆C expression are 
highlighted.   
Axl BLC CD30 CD40 CXCL16 Eotaxin-
2 
FasL IGFBP3 IGFBP5 Lix 
L-
Selectin 
E-
Selectin 
MIP-1a MIP-1g PF4 P-
Selectin 
SDF-1a TCA-3 sTNFRII VCAM-1 
GM-CSF IFNg IL-1a IL-1b IL2 IL-3 IL-4 IL-5 IL-6 IL-9 
IL-10 IL-12 IL-13 IL-17 KC MCP-1 M-CSF RANTES TNFa VEGF 
Eotaxin MIG G-CSF GITR ICAM-1 IGFBP2 IGFBP6 IGF-1 IL-12 
p40/70 
Leptin 
MCP-5 MDC MIP-2 MIP-3a OPN OPG Resistin SCF TPO VEGF-D 
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Figure 20.  Effects of EphA2 expression on osteoclast differenction factors.  
A) Knockdown of EphA2 in MDA-MB-231 cells demonstrates reduced expression 
levels of IL-6 as measured by realtime PCR.  B)  Reduced expression of EphA2 
in breast cancer cells leads to decreased release of soluble IL-6 but not RANKL  
(C) when using an ELISA for conditioned media detection. *p<0.05.  n.s. not 
significant 
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remodeling i.e. RANKL and PTHrP, revealed no statistical changes.  Reporter 
constructs developed in Dr. Greg Mundy’s lab showed changes in EphA2 status 
of MDA-MB-231 cells as well as 4T1 cells did not result in changes to PTHrP 
activity (Julie Sterling and Greg Mundy personal communication).  These results 
suggest a link between EphA2 expression and IL-6 expression, and that this 
tumor cell derived IL-6 could promote increased osteoclast differentiation.  
 
Targeting EphA2 in breast cancer cells inhibits tumor induced osteolysis in 
vivo 
 Our studies thus far suggest that EphA2 enhances osteoclast differentiation.  
Thus, we hypothesized that blocking EphA2 activity could be a novel, effective 
new therapeutic approach to inhibiting breast cancer induced osteolysis.  To 
investigate the efficacy of blocking EphA2 in breast cancer induced osteolysis we 
treated tumor-bearing animals with an activating antibody against EphA2 [191]. 
Following intratibial implantation of tumor cells, the anti-human EphA2 antibody 
or control human IgG was injected intraperitoneal every 72 until limbs were 
collected for analysis (Figure 21A).  Seven weeks post implantation of MDA-MB-
231 breast cancer cells animals were imaged for osteolytic response.  Analysis of 
animals treated with the anti-EphA2 antibody revealed a decrease in osteolysis 
as compared to human IgG control when imaged with microCt (Figure 21B).  
With respect to tumor-induced osteolysis, analysis of the tumor injected tibias 
using TRAP staining and histomorphometry revealed significantly decreased 
osteolysis in the anti-EphA2 antibody treated animal versus the IgG control 
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treatment.  The BV/TV ratio for the anti-EphA2 antibody treated animals were 
three times the total bone percentage of the IgG treated animals (Figure 21C).  In 
addition, the number of osteoclasts per millimeter of bone perimeter was two 
times greater in the IgG control treated animals versus those receiving the 
EphA2 targeted treatment (Figure 21C).  These findings suggest a role for EphA2 
in breast cancer induced osteolysis that can be attenuated via blocking EphA2 
receptor function. 
 
Tumor cell EphA2 in close proximity to osteoclasts in human breast-to-
bone metastasis. 
 Our animal models of tumor-bone interactions identified the connection 
between EphA2 activity and osteolysis.  Furthermore, targeting human breast 
cancer bone xenografts with an antibody against EphA2 revealed the possibility 
of developing a more reliable inhibitor of breast cancer induced osteolysis.  
Based on this assessment, the expression of EphA2 was examined in human 
cases of breast-to-bone metastasis (n=4).  Interestingly, EphA2 staining was 
seen throughout the tumor, but was more intense in areas closely associated 
with bone (Figure 22).  More importantly, many of these areas stained for TRAP-
positive multinucleated osteoclasts in the region that would be considered the 
tumor-bone interface.  Thus, EphA2 may not only have a role in inducing  
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Figure 21.  A therapeutic antibody against EphA2 attenuates bone 
resorption.  A) Treatment strategy for the application of the human antibody 
against EphA2 follwing MDA-MB-231 cell innoculation via intratibial injection.  B) 
Live animal imaging reconstruction of CT scans demonstrating osteolysis in IgG 
control treated animals versus those treated with the EphA2 antibody.  C) TRAP 
staining of sections from animals injected with tumor cells and treated with either 
IgG control or antibody against EphA2.  Black arrows denote osteoclast 
resorbing bone.  D)  Quantifications of stained sections show a signifcant 
difference in bone volume versus total volume (BV/TV) in the EphA2 treated 
animals as well as showing a statistical decrease in number of osteoclast in the 
EphA2 treated animals versus controls.  *p<0.05 
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soluble factors involved in osteoclast differentiation but may also have a direct 
physical interaction in mediating osteoclast differentiation and activity as 
suggested by localization of EphA2 tumor cells and osteoclast in human samples 
containing osteolysis.  
 
Discussion 
 Accumulating evidence indicates that Eph receptors and associated ephrin 
ligands play critical roles in diverse cellular processes including cell growth and 
motility.  More recently a role for these receptors and ligands in bone biology has 
emerged prompting the search for newly identified molecular pathways mediated 
by these unique receptor/ligand interactions in bone remodeling.  Many of these 
molecular pathways focus on differentiation of osteoclasts and osteoblasts and 
their regulation of bone resorption or bone formation under homeostatic 
conditions [132, 143, 145].  However, high levels of Eph receptors are associated 
with various cancers that have the ability to metastasis to bone, including breast 
cancer [1, 74].  Lesions detected in bone from breast cancers are often osteolytic 
in nature, whereby activated osteoclasts cause bone resorption releasing growth 
factors that stimulate tumor cells to grow in the local environment in turn leading 
to the release of other growth factors by the tumors to induce continued bone 
resorption. Understanding the molecular mechanisms that control the vicious 
cycle is key to developing new therapies designed to treat bone metastasis 
and/or inhibit bone cell-tumor cell interactions that induce osteolysis.  
 Recent studies into Eph receptor function in cancers have shown regulation 
106 
 
of tumor growth by EphA2 via soluble EphA2-Fc receptor treatment as well as 
overexpression of dominant negative or kinase inactive forms of the receptor in 
4T1 mammary adenocarcinoma cells [11, 88, 105].  Furthermore, studies using 
siRNA against EphA2 have demonstrated silencing EphA2 expression inhibits 
proliferation and tumor growth in mesothelioma and ovarian cancer [90, 91].  
These reports reveal a direct role of EphA2 regulation in tumor growth and 
subsequent studies additionally revealed a significant role for EphA2 in 
promotion of tumor angiogenesis.  EphA2 deficient studies revealed a failure of 
vascular endothelial cells to migrate, assemble, and incorporate into blood 
vessels when co-cultured with tumor cells in vitro and in vivo [88, 105].  In 
addition, tumor cells implanted into EphA2 null mice also show decreases in 
tumor volume, and microvascular density [105, 106].  Thus, an antibody against 
EphA2 would likely impact tumor growth and cytokine production (as 
demonstrated through EphA2 null studies of angiogenesis) simultaneously 
making EphA2 a great target for breast cancer metastasis. 
 Therefore, in the context of bone cell-tumor cell interactions, we hypothesize 
that blocking EphA2 will result in a decrease of osteoclast differentiation and 
activation thus breaking the vicious cycle and offering an effective means to 
control bone metastasis.  This hypothesis is supported by our in vivo studies 
demonstrating the efficacy of a therapeutic anti-EphA2 antibody in reducing 
osteolytic disease in human breast cancer bone xenografts.
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Figure 22.  EphA2 localization to bone in human breast-to-bone metastasis.  
Tumor cell EphA2 positive staining was detected at the bone tumor interface and 
corresponded to areas of high osteolysis as measured by TRAP staining for 
presence of osteoclast.  Representative staining of sections for TRAP and EphA2 
are depicted in the above panels.  Arrows denote bone and arrowheads denote 
EphA2 positive tumor cells at the bone tumor interface. 
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 The first example of Eph/ephrin function in bone came using an ephrinB1 
knockout mouse model that demonstrated skeletal abnormalities including cleft 
palate, skull shortening, asymmetric pairing of the ribs, and sternebral fusions 
[138].  Continued studies on class B Eph receptors and ligands also 
demonstrated an inhibitory function for ephrinB2 on osteoclast differentiation in 
contrast to the stimulatory function of EphB4 on osteoblasts [143].  Most recently, 
a similar function for A class Eph receptors in bone homeostasis was 
established.  EphA2 on osteoblasts enhance osteoclastogenesis while inhibiting 
osteoblast differentiation through increased reverse signaling by ephrinA2 on 
osteoclast precursors [145].  In our studies of tumor cell induced osteolysis, we 
focused on tumor cell EphA2 forward signaling in regulation of soluble factors 
released from tumor cells to influence osteoclast differentiation in vitro.  However, 
our in vivo studies, where physical interaction between bone and tumor cells is 
occurring, it is possible that a similar effect to bone homeostasis is being 
propagated through reverse ephrin signaling on osteoclasts.  Increased 
expression of EphA2 on tumor cells could increase reverse signaling activity on 
osteoclast precursors leading to more osteoclast differentiation.  Thus, tumor 
cells in this context mimic osteoblast function via binding to osteoclast precursors 
to promote more Eph/ephrin interactions and reverse signaling.  This 
differentiation is inhibited when EphA2 expression is deleted via shRNA studies 
or with an active block of the EphA2 receptor i.e. activating antibody.  
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 The temporal and spatial specificity of many of the signals transduced by 
Eph/ephrins ensures proper development of tissues and organs, but additional 
research suggests that aberrations in many of these same pathways also 
contributes to tumorigenesis and/or progression.  Thus, it is likely these Eph and 
ephrin interactions have a key role in aberrant bone remodeling due to increased 
expression in tumors or bone cell-tumor cell interactions.  Breast cancer and 
multiple myeloma are associated with bone metastases that exhibit high levels of 
osteolysis while prostate cancers usually have higher levels of bone formation, 
yet all have altered levels of Eph/ephrin signaling.  In multiple myeloma, 
osteolysis is driven by lack of EphB4 expression on osteoblasts causing an 
inhibition of new bone formation (A. Bates, J Edwards personal communication). 
Tissue microarray data from prostate cancer metastasis foci in lymph node, liver, 
and bone revealed decreased ephrinA1 expression levels in bone metastasis 
[147], where-as other studies show decreased EphA1 receptor levels in 
osteolytic giant cell tumors of bone [148, 149].  The differences among these 
cancer models in bone response could be a result of differential regulation of Eph 
receptor and ephrin ligand expression and signaling.  It is possible that reverse 
signaling by ephrin ligands promote osteoclast differentiation, and Eph receptor 
expression serves to promote or influence this reverse signaling.  Studies 
demonstrate a decrease in EphB4 receptor levels are associated with an 
increase in osteolysis through the ability of ephrinB2 to transduce signals through 
its cytoplasmic domain that contains a phosphorylation site.  This is in contrast to 
alterations in EphA class signaling where ligands do not have cytoplasmic 
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portions capable of phosphorylation.  Thus, increased expression of EphA 
receptors can induce more reverse signaling of ephrin ligands where also 
triggering forward signaling of the receptor to release cytokines promoting 
osteoclast differentiation.  The decrease in ephrinA1 levels of prostate cancer 
metastasis to bone and the increase in bone formation of this model is most likely 
due to decreased osteoclast activity.  The loss of ephrinA1 on the osteoclast 
precursor’s surface attenuates and limits the response of EphA receptors that 
would bind to induce reverse signaling and osteoclast differentiation. Thus, 
coupling is disrupted and an imbalance favoring bone formation results. 
 Inhibiting EphA2 by deletion or blocking activity leads to impaired osteoclast 
development as measured by osteoclast differentiation assays and functional 
assays including in vivo analysis.  Our studies have also revealed decreases in 
cytokine production by cultured tumor cells (both human and murine) when 
EphA2 activity is inhibited.  The list of cytokines decreased upon EphA2 inhibition 
consists of many inflammatory factors that have been associated with osteoclast 
precursors and mature osteoclast function (e.g. GMCSF, MCSF, MIP1, and IL-6).  
IL-6 has the capacity to influence many biological events including bone 
remodeling through stimulating production of PTHrP that decreases production of 
the RANKL decoy receptor OPG (osteoprotegerin) and increases the osteoblast 
production of RANKL.  In our studies changes to OPG and PTHrP were not 
detected and RANKL was not changed upon inhibition of EphA2. It has been well 
recognized, particularly in multiple myeloma, that the interaction between stromal 
cells and tumor cells in the bone marrow contributes to tumor progression [224].  
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Adhesion of myeloma cells to MSC (mesenchymal stem cells) through cell 
adhesion molecules or integrins induces the expression of IL-6 by MSC [225].  
We first suspected this was the case as well, but our studies have revealed that 
tumor cells are able to release these cytokines independently of MSC or 
osteoblasts suggesting that cell-cell contact is not required.  Thus, tumor cell 
expressed EphA2 controls the release of soluble IL-6 into condition media.  How 
EphA2 regulates IL-6 release and potential function upon osteoclast precursors 
is not well understood, though we are currently investigating this. 
 In conclusion this study reveals a novel function of EphA2 signaling in tumor 
cell-bone cell interactions involved in osteoclastogenesis and osteolysis 
associated with breast cancer metastasis.  Furthermore, our data suggest the 
benefits for targeting EphA2 in advanced stage breast cancer disease associated 
with bone metastasis to disrupt the vicious cycle.  Our data support the rationale 
for continued investigation into targeting cell-cell interactions via Eph receptors 
and ligands as a way to treat osteolytic bone disease that would offer the 
potential for increased therapeutic options available to patients suffering from this 
painful disease. 
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CHAPTER IV 
 
CONCLUSIONS 
 
 The Eph receptors and their corresponding ephrin ligands are a relatively 
young receptor tyrosine kinase family.  The first member of this family was 
discovered a little over 20 years ago, but since then the study of this, the largest 
known family of receptor tyrosine kinases, has evolved considerably.  Over the 
past 20 years, the known biological functions of Eph receptors and their ligands 
have experienced tremendous growth, as has the scope and diversity of Eph and 
ephrin-mediated signaling.  Correspondingly, scientific interest in the field has 
grown during this time as measured by the boom in publications tallied through 
Pubmed.  Eph receptors and ephrins have emerged as key regulators of 
physiological and pathological processes in multiple diseases and during normal 
homeostasis and development.  Despite our current knowledge of Eph receptors 
and their ligands in biology, a more complete understanding of function and 
dysregulation in the context of cancer as well as development has yet to be 
achieved.  The work presented here focuses on one specific Eph receptor and 
represents the balance between developmental biology and metastatic cancer 
through the function of this receptor, EphA2, and its ligands. 
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 In this thesis we demonstrate for the first time the developmental effect of 
EphA2 receptor regulation of normal growth and branching morphogenesis in the 
mammary gland.  Mammary epithelial branching morphogenesis is a complex 
developmental process during which an extensive network of branched ducts 
forms from a rudimentary epithelial bud [reviewed in [64, 201]].  In response to 
hormonal stimuli, terminal end buds (TEB) form at the tips of the ducts and 
invade into the surrounding stroma.  New primary ducts then form by bifurcation 
of the TEBs and secondary side-branches sprout laterally from the trailing ducts.  
This process is reiterated through branching and tissue remodeling until the 
entire mammary fat pad is filled with a ductal tree in the virgin gland. 
 Wildtype animals at the onset of puberty, approximately 3.5 weeks, will 
undergo rapid proliferation and invade the stroma directionally from the 
rudimentary mammary epithelium anlagen, giving rise to a fully branched ductal 
tree that completely fills the mammary fat pad by 10 weeks of age.  EphA2 
deficient animals, in contrast, exhibit severe growth retardation displayed by 
reduced fat pad filling and penetration through the mammary fat pad as 
measured by whole mount analysis (Chapter II).  This defect is more prominent 
at 5 and 6 weeks of age and can persist through adulthood despite some 
compensation taking place [5].  The defects in outgrowth and branching in EphA2 
deficient mice are a result of reduced proliferation as determined by tissue 
staining for PCNA, and not related to apoptosis as measured by TUNEL.  High 
proliferative activity was observed in 5 and 6 week old animals, while EphA2 
deficient animals had reduced PCNA staining in age matched animals.  The 
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differences in proliferation paralleled the defects observed in the whole mount 
analysis of age group involved in the study.  Thus, loss of EphA2 impairs normal 
development and architecture of the mammary epithelial tree.   
 Mammary gland branching morphogenesis is regulated by endocrine 
hormones and local paracrine interaction between the developing epithelial ducts 
and their adjacent mesenchymal stroma.  Based on reciprocal transplantation 
studies we were able to show EphA2 function was specific to mammary 
epithelium, rather than mesenchymal stroma, in regulation of growth and 
branching of the mammary gland ducts.  Although the mediators of the complex 
interaction in mammary gland development are not fully characterized, receptor 
tyrosine kinases (RTK) are among the critical regulators of branching 
morphogenesis [57].  Hepatocyte growth factor/scatter factor (HGF/SF), a 
mesenchymal derived mitogen and morphogen, induces branching 
morphogenesis through its receptor c-Met, which is expressed on mammary 
epithelial cells [reviewed in [202, 203]].  A number of factors acting in a paracrine 
fashion are known to regulate mammary gland development via branching 
morphogenesis [212].  In particular, HGF promotes ductal outgrowth and tubule 
formation in the mammary gland [202]. 
 Data derived from reciprocal transplant experiment were validated in an in 
vitro system where specific morphogens can be manipulated to determine their 
effect on mammary branching.  Primary mammary cells isolated from wild-type 
animals branched and invaded the three-dimensional matrix where-as cells 
isolated from the EphA2 null animals displayed diminished branching relative to 
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the wild-type controls.  In response to HGF stimulation, wild-type spheroids 
undergo extensive remodeling and branching.  In contrast, EphA2-deficient 
spheroids fail to undergo branching morphogenesis, displaying significantly fewer 
branches relative to wild-type cells in response to HGF stimulation.  
Overexpression of wild-type EphA2 receptor in primary mammary epithelial cells 
via adenovirus transduction not only rescued phenotypes in EphA2-deficient 
cells, but also drastically enhanced branching morphogenesis in wild-type cells.  
Thus, we have shown EphA2-deficiency inhibits HGF-induced mammary 
epithelial cell branching morphogenesis. 
 Dynamic regulation of the actin cytoskeleton is critical in a number of cellular 
processes including cell migration and branching morphogenesis.  RhoA 
GTPases are key regulators of actin stress fiber formation and are necessary for 
cell migration [213, 214].   Moreover, Ewald et al. recently reported that inhibition 
of ROCK kinase, a downstream effector of RhoA, results in hyperbranched 
mammary epithelium in organoid cultures [216], suggesting that RhoA is crucial 
for proper branching morphogenesis in mammary epithelial development.  We 
show here through inhibitor studies that EphA2 functions downstream of HGF to 
regulate RhoA GTP to induce mammary gland branching.  Furthermore, we show 
that a balance of RhoA is critical as too much or too little RhoA leads to similar 
observations.  
 The data reported herein also shows for the first time the function of EphA2 in 
breast cancer induced osteolysis.  Though other studies have demonstrated the 
effects of Eph receptors and their ligands in maintaining bone homeostasis we 
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show the effects of EphA2 in the context of tumor progression.  Our studies 
demonstrate the ability of breast tumor cells with high levels of EphA2 to induce 
osteolysis in the bone through increased osteoclast differentiation that eventually 
leads to more functionally active osteoclast (Chapter III).  Inhibition of EphA2 
activity in human and mouse mammary adenocarcinoma cells leads to 
decreased osteolysis in vivo, whereas in vitro we see inhibition of osteoclast 
differentiation as measured by TRAP staining.  More importantly our studies 
show the efficacy of a therapeutic antibody targeting EphA2 in vivo that leads to 
reduced osteolysis as measured by microCt scanning and bone 
histomorphometry analysis.  The efficacy of this antibody demonstrated here 
suggests the potential benefit for use in inhibition of bone osteolysis.  
 
Future Directions 
 The ability of Eph receptors to mediate ligand independent and dependent 
signaling that promote different outcomes is one of the main reasons why further 
studies should be conducted on Eph/ephrin signaling.  Furthermore, the 
controversy that exists in the field of Eph/ephrin biology in terms of oncogenic 
versus tumor suppressive functions and the context dependent signaling displays 
the many questions that remain to be answered [226].  One specific question that 
must be addressed involves teasing out specific signaling activities of different 
Eph receptors in response to or in the absence of their ligands.  Our lab has 
developed a working model to conceptionalize the paradoxical effects of Eph 
signaling (Figure 23).  Under physiological conditions, Eph receptors and ligands 
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interact at the cell surface, inhibiting activation of various pathways through 
ligand-mediated receptor internalization and degradation.  Blockade of these 
pathways by Eph receptors and their ligands is critical in development as 
demonstrated by studies showing aberrant neuronal circuitry, remodeling of 
blood vessels, tissue homeostasis, tissue boundary formation, and glandular 
development when Eph/ephrin interactions are disrupted (Chapter II and 
reviewed in [1, 227].  We believe cancer cells, however, have developed 
mechanisms to prevent ligand dependent signaling leading to tumorigenesis.  
Disruption of cell-cell junctions and mislocalization of Eph receptors and ephrins 
on the cell surface is one such mechanism.  Also, studies have demonstrated the 
ability of known oncogene products in cancers to cross talk with Eph receptor 
kinases through heterodimerization in order to cause activation of downstream 
cascades independent of any ligand binding (Table 1 and references therein).  
Therefore we hypothesize ligand dependent signaling apparently promotes tumor 
suppressive functions, where-as ligand independent signaling likely induces an 
oncogenic function.  
 Future studies using single and double knockout mouse models to delineate 
the differences between receptor and ligand function in both development and  
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Figure 23. Working model for Eph receptor function in tumor promotion 
and tumor suppression. In normal cells, engagement of Eph receptors with 
ephrins on adjacent cells in trans induces receptor forward signaling, leading to 
inhibition of Ras/mitogen-activated protein kinase (MAPK) activity, or 
suppression of Crk activation via Abl kinase activity, and tumor suppression. In 
tumor cells, disruption of cell-cell junctions inhibits Eph receptor interaction with 
endogenous ephrins in trans. In addition, Eph receptors are often upregulated 
whereas ephrins are downregulated. Crosstalk between Eph receptors and other 
receptor tyrosine kinases such as ErbB2 and epidermal growth factor receptor 
(EGFR) results in increased activity of the Ras-MAPK pathway and the RhoA 
GTPase, and enhanced tumor malignancy.  From [167]
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tumorigenesis would be very beneficial in confirming this hypothesis.  To 
complement the studies done with the EphA2 KO animal in development (see 
Chapter II) and tumorigenesis [5] we have proposed and begun studies to 
characterize the ephrinA1 KO animal in development and tumorigenesis.  The 
EphA2 KO and ephrinA1 KO animals are ideal tools to begin a study to sort out 
receptor/ligand signaling complexes in context dependent situations.  
Independent investigations and characterization of the ephrinA1 KO mouse will 
follow a similar approach as outlined in Chapter II for the EphA2 KO mouse to 
determine the function of ephrinA1 on mammary gland development and 
tumorigenesis.  As discussed already, in normal cells EphA and ephrinA are 
expressed at low levels and interact in trans between adjacent cells [5, 35, 88].  
In addition my work on EphA2 deficiency suggest an impaired mammary 
epithelial growth and branching while work from our lab reported impaired ErbB2 
dependent tumorigenesis in vivo [5, 69].  Preliminary data of the ephrinA1 ligand 
knockout mouse, in contrast, shows increased epithelial branching and 
hyperplasia.  Analysis of EphA2 and ephrinA1 in a panel of human breast cancer 
cell lines revealed that EphA2 and ephrinA1 expression are mutually exclusive 
and this expression pattern is seen in a significant portion of lymph node 
metastasis from human breast cancer samples [8].  Thus, we hypothesize an 
interaction between EphA2 and ephrinA1 inhibits growth and invasiveness in the 
mammary gland.  Our theory suggest ephrinA1 KO animals would suppress 
EphA2 forward signaling and receptor internalization and degradation thereby 
leading to inhibition of quiescent epithelial cells.  This disruption of EphA2 and 
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ephrinA1 signaling would enable EphA2 protein levels to increase on the 
membrane surface to promote growth through the Ras/Erk and Rho pathways 
leading to malignant transformation and further elevating the oncogenic effect of 
EphA2.   
 
Eph receptor crosstalk, ligand independent signaling 
 Another approach to understanding the roles of ligand-dependent and ligand-
independent signaling of EphA2 will be to take the advantage of the crosstalk 
between EphA2 and ErbB2.  Reports from our lab demonstrated a physical 
interaction between EphA2 and ErbB2 as well as a functional interaction leading 
to phosphorylation of EphA2.  In addition, this crosstalk leads to therapeutic 
resistance in breast cancer and speculation of such in lung cancer.  Crossing the 
ephrinA1 KO animals with the MMTV-Neu breast cancer model should assist in 
determining the ligand dependent and independent signaling roles in malignancy.  
I would expect that ephrinA1 KO animals would have increased branching and 
growth in development of the epithelial (opposite phenotype of EphA2 receptor 
KO) in the context of mammary gland development.  Also, we would expect 
these animals to display mammary epithelial hyperplasia and hyperbranching 
and potentially develop tumors spontaneously.  Outside of development, we 
hypothesize the ephrinA1 KO animals crossed to the MMTV-Neu breast cancer 
model will enhance tumorigenesis as well as metastasis due to the suspected 
release of inhibition on EphA2.  It would be interesting to see if the deficiency of 
ephrinA1 can disrupt interactions with EphA2 to accelerate tumorigenesis in this 
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model since the native ligand is gone.  I would expect a reduction in tumor 
latency and an increase in tumor volume and propensity to metastasize when 
ephrinA1 is absent from the cell surface allowing EphA2 receptors to remain on 
the cell surface and not be internalized.  
 Furthermore, utilizing the ephrinA1 KO animal and mating it to the EphA2 KO 
animal for a double KO could be used to determine if tumorigenesis enhanced by 
ephrinA1 deficiency is EphA2 dependent.  Loss of both the receptor and ligand 
likely will reduce tumorigenesis to mimic the latency and progression in the 
parental MMTV-Neu model.  Likewise, the double knockout could mimic a wild 
type control animal in terms of developmental despite the function of Ephs and 
ephrins in heart development, vessel formation, tissue boundaries, and neuronal 
patterning due to the loss of the both receptor and ligand leading to a balance as 
opposed to an imbalance with single knockouts.  Investigations into the role of 
EphA2 as an oncogene could be greatly enhanced as well with the assistance of 
the ephrinA1 KO model.  An EphA2 mammary epithelial transgenic mouse model 
has been developed in our lab and preliminary results show overexpression of 
EphA2 increases tumor onset, tumor burden, tumor number and metastasis. 
However, these values are modest and confirming overexpression by 
immunoblot has been difficult.  We believe that this modest response, despite 
having a homozygous line for the EphA2 transgene, could be a result of 
endogenous ephrinA1 expression limiting the degree by which EphA2 is 
overexpressed on the cell surface.  Thus a critical experiment in determining the 
oncogenic effect of EphA2 would be through crossing this transgenic animal for 
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EphA2 with the ephrinA1 KO to potentially increase and stabilize the expression 
levels of EphA2.  I would expect a much greater expression of EphA2 and 
subsequent increases of tumor onset, burden, numbers and metastasis beyond 
modest differences.   
 
Reverse signaling via ephrin ligand 
 One of the unique characteristics of Eph/ephrin signaling is the ability of the 
receptor expressing cell as well as the ephrin expressing cell to function in signal 
transduction pathways.  The ability of ephrin ligands to signal is known as 
reverse signaling and is an area of active investigation with the A class ephrins.  
Using ephrinA1 KO animals alone or crossed with breast tumor models we will 
have the opportunity to investigate the role of A class reverse signaling in cancer 
cells as the context of signaling has proven to be critical in response or outcome.  
Most of the studies that have been presented thus far have focused on the Eph 
receptor and understanding how it signals in development, tumor development, 
and interactions with the microenvironment.  Ephrin ligands are also present on 
tumor cells suggesting they may also have a role in tumorigenicity via reverse 
signaling.  Similar to the Eph receptors, both pro- and anti-tumorigenic properties 
have been attributed to ephrin molecules themselves.   EphrinB1 tyrosine 
phosphorylation disrupts binding of Par6, a scaffolding protein, to promote tight 
junctions and anti-tumorigenic potential in colon cancer cell studies [228].  
EphrinA5 also demonstrates anti-tumorigenic properties in glioma through down 
regulation of EGFR levels [229].  In contrast, ephrinA5 reverse signaling 
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activates Fyn to induce murine fibroblast transformation measured by cell growth 
in soft agar, invasion, and morphology changes [230].  Reports for ephrinB 
reverse signaling suggest lipid raft localization induces Rac1 activation to 
increase cellular migration, invasion and pro-tumorigenic activities [231-233].  
Continued research with transgenic and knockout mouse models much like those 
proposed earlier in this section will be instrumental in determining the precise 
roles of reverse signaling.   
 
Role of EphA2 in bone development and osteolysis 
 Other important studies center on the role of ephrin ligand and Eph receptors 
in bone homeostasis as well as tumor induced osteolysis.  Considering that 
ephrin ligand and Eph receptor interactions are critical in bone homeostasis for 
both the A class and B class receptors [143, 145], it will be interesting to look at 
bone development in both the EphA2 KO and ephrinA1 KO animals to see if 
there are differences in bone density as measured by microCt or faxitron 
analysis.  We would expect there to be some sort of difference in bone density 
since the ability of osteoclast and osteoblast cells to directly interact would be 
inhibited with the loss of the receptor or ligand respectively, thus causing a block 
in bidirectional signaling.   
 Our study has focused and investigated the final stage in the metastatic 
cascade by looking at tumor cell bone cell interactions.  Previous results from our 
lab have demonstrated the loss of EphA2 can reduce the ability and degree by 
which breast cancer cells metastasize [11].  It would be interesting to see how 
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orthotopic injections of tumor cells lacking EphA2 function would affect bone 
metastasis, and whether EphA2 is only involved in osteoclast differentiation and 
function or if there is a greater role for EphA2 in directing cells to the bone.  
Likewise, intratibial injections into the ephrinA1 KO mouse model would be of 
great interest to see if host loss of the ligand exacerbates the ability of EphA2 to 
induce osteolysis.  
 
Targeting EphA2 as a treatment 
 Currently there is no cure or effective treatment available for patients suffering 
with bone metastasis.  The treatments available for these patients such as 
bisphosphonates, radiation, surgery and chemotherapy are only palliative.  
Finding new mechanisms underlying cell-cell communication between bone cells 
and tumor cells is key for developing better more effective treatments against 
bone metastasis.  Our results suggest that targeting of Eph receptors, specifically 
EphA2, would be beneficial to patients through inhibition of osteoclast 
differentiation and subsequent activation.  The strength of EphA2 as a drug 
target lies in the expression profile of the protein.  It is found in many adult 
epithelial tissues such as brain, skin, ovary, and breast but at low levels [234].  
Cancers arising from these epithelial tissues, conversely, are usually associated 
with high expression levels of EphA2 [1, 74].  The abundance of EphA2 on 
tumors provides an ideal cancer target as the EphA2 antibody can target the 
more abundant tumor EphA2 opposed to less expressed normal tissue EphA2 
receptor levels.  The lower expression of EphA2 in normal tissue also will limit 
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the toxicity and side effects associated with this treatment, as the antibody would 
target the more abundant tumor EphA2.  Phase I trials looking for adverse effects 
associated with treatment would need to focus on tissues composed of high 
levels of epithelial cells (i.e. kidney, skin, intestines etc.) where EphA2 would be 
expressed normally to investigate the ability of targeting EphA2 and binding on 
normal tissue.  In addition, wound healing could potentially develop as an 
adverse effect with studies showing a critical role between EphA2 receptor and 
ephrinA1 ligand in angiogenesis (reviewed in [206, 235]). 
 Patients selected for inclusion in a trial investigating the toxicity and efficacy 
of an EphA2 targeting antibody would have positive staining for EphA2 in their 
primary breast tumor by IHC as a vast majority of breast cancers have increased 
EphA2 expression but not all do.  Furthermore, preclinical data presented in this 
thesis would suggest a better response in patients that have advance breast 
cancer with metastasis to bone.  Using the aforementioned selected patient 
cohort, the primary outcome measure of the clinical trial would focus on the 
response in osteolytic lesions associated with breast cancer metastases to bone.  
Inhibition of new osteolytic lesions or reductions in lesion number or size from 
decreased osteoclast function would be viewed as a positive sign for EphA2 
targeted treatments in breast cancer bone metastasis.  Continued studies and a 
larger multi-centered trial would assist in determining if an anti-EphA2 antibody 
treatment alone or as part of a combination offered a better overall response, 
longer duration, and higher progression free response versus the current 
chemotherapy standard of care in breast cancer metastasis to bone 
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bisphosphonates. 
 Aside from attenuation of osteolysis in breast cancer metastasis to bone via 
inhibition of EphA2, it would be beneficial to see if cell-cell interactions between 
Eph receptors and ephrin ligands are critical in the ability of the primary tumor to 
metastasize to bone.  An important study would be to use the knockout mouse 
models developed in our lab for the Eph receptors and ephrin ligands and 
combine them with orthotopic models of cancer.  This study has been proposed 
and attempted in our lab, however the majority of cells colonize the lungs before 
they colonize the bone as they metastasize.  Thus, results in these studies are 
often inconclusive due to the animal succumbing to metastatic disease in the 
lungs before bone lesions are detectable.  Intracardiac injections, as well as the 
intratibial injections, are feasible methods used to circumvent the lung 
metastases, however these are not effective alternatives to looking at cell-cell 
interactions through the metastatic process that occur in orthotopic xenografts.  
The development of particular breast cancer cells with a higher propensity to 
metastasize to bone rather than lung are under development by multiple groups 
for future use in understanding metastasis [236-238].  These studies would help 
in determining a potential role of Eph receptors in the “bone metastasis niche,” 
likewise utilizing the ephrinA1 KO animals we can investigate the potential 
contributions from host derived Eph/ephrin interactions in metastasis.  
Considering the role of ephrinA1 and EphA2 in tumor angiogenesis it is likely that 
tumor-host interactions have a critical role in metastasis leading up to tumor cell 
bone interactions.   
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 In conclusion we have shown a role for EphA2 in mammary gland 
development through regulation of Rho activity and epithelial branching 
influenced by HGF.  In addition, this dissertation highlights the detrimental effects 
of EphA2 expression on breast cancer cells that are able to interact with existing 
stroma of the bone to induce osteoclast differentiation and activation that leads to 
osteolysis.  Therefore, novel therapeutic agents focusing on major components 
of the vicious cycle and/or blocking cell-cell interactions between bone and tumor 
cells will improve the current treatment options offered to patients suffering from 
lytic bone disease.  Continued development of specific inhibitors to Eph receptors 
or therapies that block their activity, like those highlighted and included in this 
dissertation, would benefit many of these patients who have a poor response to 
bisphosphonates or other traditional treatment methods.  Furthermore, targeting 
Eph receptors and their ability to mediate activity via cell surface binding may be 
helpful as adjuvants in combination with bisphosphonates or other inhibitors. 
128 
 
REFERENCES 
 
1. Pasquale, E.B., Eph-ephrin bidirectional signaling in physiology and disease. 
Cell, 2008. 133(1): p. 38-52. 
2. Kullander, K. and R. Klein, Mechanisms and functions of Eph and ephrin 
signalling. Nat Rev Mol Cell Biol, 2002. 3(7): p. 475-86. 
3. Fang, W.B., et al., Identification and functional analysis of phosphorylated 
tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem, 2008. 
283(23): p. 16017-26. 
4. Binns, K.L., et al., Phosphorylation of tyrosine residues in the kinase domain and 
juxtamembrane region regulates the biological and catalytic activities of Eph 
receptors. Mol Cell Biol, 2000. 20(13): p. 4791-805. 
5. Brantley-Sieders, D.M., et al., The receptor tyrosine kinase EphA2 promotes 
mammary adenocarcinoma tumorigenesis and metastatic progression in mice by 
amplifying ErbB2 signaling. J Clin Invest, 2008. 118(1): p. 64-78. 
6. Pratt, T., et al., The winged helix transcription factor Foxg1 facilitates retinal 
ganglion cell axon crossing of the ventral midline in the mouse. Development, 
2004. 131(15): p. 3773-84. 
7. Pratt, R.L. and M.S. Kinch, Ligand binding up-regulates EphA2 messenger RNA 
through the mitogen-activated protein/extracellular signal-regulated kinase 
pathway. Mol Cancer Res, 2003. 1(14): p. 1070-6. 
8. Macrae, M., et al., A conditional feedback loop regulates Ras activity through 
EphA2. Cancer Cell, 2005. 8(2): p. 111-8. 
9. Noren, N.K. and E.B. Pasquale, Eph receptor-ephrin bidirectional signals that 
target Ras and Rho proteins. Cell Signal, 2004. 16(6): p. 655-66. 
10. Fang, W.B., et al., Overexpression of EPHA2 receptor destabilizes adherens 
junctions via a RhoA-dependent mechanism. J Cell Sci, 2008. 121(Pt 3): p. 358-
68. 
129 
 
11. Fang, W.B., et al., A kinase-dependent role for EphA2 receptor in promoting 
tumor growth and metastasis. Oncogene, 2005. 24(53): p. 7859-68. 
12. Menges, C.W. and D.J. McCance, Constitutive activation of the Raf-MAPK 
pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular 
arrest through the EphA2 receptor. Oncogene, 2008. 27(20): p. 2934-40. 
13. Larsen, A.B., et al., Activation of the EGFR gene target EphA2 inhibits epidermal 
growth factor-induced cancer cell motility. Mol Cancer Res, 2007. 5(3): p. 283-
93. 
14. Warner, N., L.E. Wybenga-Groot, and T. Pawson, Analysis of EphA4 receptor 
tyrosine kinase substrate specificity using peptide-based arrays. FEBS J, 2008. 
275(10): p. 2561-73. 
15. Luo, H., et al., EphB6 crosslinking results in costimulation of T cells. J Clin 
Invest, 2002. 110(8): p. 1141-50. 
16. Salvucci, O., et al., EphB2 and EphB4 receptors forward signaling promotes 
SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood, 
2006. 108(9): p. 2914-22. 
17. Zhuang, G., et al., Elevation of receptor tyrosine kinase EphA2 mediates 
resistance to trastuzumab therapy. Cancer Res, 2010. 70(1): p. 299-308. 
18. Pasquale, E.B., Eph receptor signalling casts a wide net on cell behaviour. Nat 
Rev Mol Cell Biol, 2005. 6(6): p. 462-75. 
19. Sharfe, N., et al., Ephrin stimulation modulates T cell chemotaxis. Eur J Immunol, 
2002. 32(12): p. 3745-55. 
20. Deroanne, C., et al., EphrinA1 inactivates integrin-mediated vascular smooth 
muscle cell spreading via the Rac/PAK pathway. J Cell Sci, 2003. 116(Pt 7): p. 
1367-76. 
21. Tanaka, M., R. Kamata, and R. Sakai, EphA2 phosphorylates the cytoplasmic tail 
of Claudin-4 and mediates paracellular permeability. J Biol Chem, 2005. 
280(51): p. 42375-82. 
130 
 
22. Miao, H., et al., Activation of EphA2 kinase suppresses integrin function and 
causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol, 2000. 2(2): p. 62-
9. 
23. Zantek, N.D., et al., E-cadherin regulates the function of the EphA2 receptor 
tyrosine kinase. Cell Growth Differ, 1999. 10(9): p. 629-38. 
24. Prevost, N., et al., Eph kinases and ephrins support thrombus growth and stability 
by regulating integrin outside-in signaling in platelets. Proc Natl Acad Sci U S A, 
2005. 102(28): p. 9820-5. 
25. Yokote, H., et al., Trans-activation of EphA4 and FGF receptors mediated by 
direct interactions between their cytoplasmic domains. Proc Natl Acad Sci U S A, 
2005. 102(52): p. 18866-71. 
26. Gu, C. and S. Park, The EphA8 receptor regulates integrin activity through 
p110gamma phosphatidylinositol-3 kinase in a tyrosine kinase activity-
independent manner. Mol Cell Biol, 2001. 21(14): p. 4579-97. 
27. Dalva, M.B., et al., EphB receptors interact with NMDA receptors and regulate 
excitatory synapse formation. Cell, 2000. 103(6): p. 945-56. 
28. Cortina, C., et al., EphB-ephrin-B interactions suppress colorectal cancer 
progression by compartmentalizing tumor cells. Nat Genet, 2007. 39(11): p. 
1376-83. 
29. Ethell, I.M., et al., EphB/syndecan-2 signaling in dendritic spine morphogenesis. 
Neuron, 2001. 31(6): p. 1001-13. 
30. Zisch, A.H., et al., Tyrosine phosphorylation of L1 family adhesion molecules: 
implication of the Eph kinase Cek5. J Neurosci Res, 1997. 47(6): p. 655-65. 
31. Trivier, E. and T.S. Ganesan, RYK, a catalytically inactive receptor tyrosine 
kinase, associates with EphB2 and EphB3 but does not interact with AF-6. J Biol 
Chem, 2002. 277(25): p. 23037-43. 
32. Egea, J. and R. Klein, Bidirectional Eph-ephrin signaling during axon guidance. 
Trends Cell Biol, 2007. 17(5): p. 230-8. 
131 
 
33. Davy, A., et al., Compartmentalized signaling by GPI-anchored ephrin-A5 
requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev, 1999. 
13(23): p. 3125-35. 
34. Davy, A. and S.M. Robbins, Ephrin-A5 modulates cell adhesion and morphology 
in an integrin-dependent manner. EMBO J, 2000. 19(20): p. 5396-405. 
35. Noren, N.K., et al., The EphB4 receptor suppresses breast cancer cell 
tumorigenicity through an Abl-Crk pathway. Nat Cell Biol, 2006. 8(8): p. 815-25. 
36. Miao, H., et al., Activation of EphA receptor tyrosine kinase inhibits the 
Ras/MAPK pathway. Nat Cell Biol, 2001. 3(5): p. 527-30. 
37. Miao, H., et al., EphA2 mediates ligand-dependent inhibition and ligand-
independent promotion of cell migration and invasion via a reciprocal regulatory 
loop with Akt. Cancer Cell, 2009. 16(1): p. 9-20. 
38. Shamah, S.M., et al., EphA receptors regulate growth cone dynamics through the 
novel guanine nucleotide exchange factor ephexin. Cell, 2001. 105(2): p. 233-44. 
39. Fukai, J., et al., EphA4 promotes cell proliferation and migration through a novel 
EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol 
Cancer Ther, 2008. 7(9): p. 2768-78. 
40. Adams, R.H. and R. Klein, Eph receptors and ephrin ligands. essential mediators 
of vascular development. Trends Cardiovasc Med, 2000. 10(5): p. 183-8. 
41. Flanagan, J.G. and P. Vanderhaeghen, The ephrins and Eph receptors in neural 
development. Annu Rev Neurosci, 1998. 21: p. 309-45. 
42. Cheng, H.J. and J.G. Flanagan, Identification and cloning of ELF-1, a 
developmentally expressed ligand for the Mek4 and Sek receptor tyrosine kinases. 
Cell, 1994. 79(1): p. 157-68. 
43. Drescher, U., et al., In vitro guidance of retinal ganglion cell axons by RAGS, a 
25 kDa tectal protein related to ligands for Eph receptor tyrosine kinases. Cell, 
1995. 82(3): p. 359-70. 
132 
 
44. Flenniken, A.M., et al., Distinct and overlapping expression patterns of ligands 
for Eph-related receptor tyrosine kinases during mouse embryogenesis. Dev Biol, 
1996. 179(2): p. 382-401. 
45. McBride, J.L. and J.C. Ruiz, Ephrin-A1 is expressed at sites of vascular 
development in the mouse. Mech Dev, 1998. 77(2): p. 201-4. 
46. Takahashi, H. and T. Ikeda, Molecular cloning and expression of rat and mouse 
B61 gene: implications on organogenesis. Oncogene, 1995. 11(5): p. 879-83. 
47. Frieden, L.A., et al., Regulation of heart valve morphogenesis by Eph receptor 
ligand, ephrin-A1. Dev Dyn, 2010. 239(12): p. 3226-34. 
48. Wang, H.U., Z.F. Chen, and D.J. Anderson, Molecular distinction and angiogenic 
interaction between embryonic arteries and veins revealed by ephrin-B2 and its 
receptor Eph-B4. Cell, 1998. 93(5): p. 741-53. 
49. Adams, R.H., et al., Roles of ephrinB ligands and EphB receptors in 
cardiovascular development: demarcation of arterial/venous domains, vascular 
morphogenesis, and sprouting angiogenesis. Genes Dev, 1999. 13(3): p. 295-306. 
50. Gerety, S.S., et al., Symmetrical mutant phenotypes of the receptor EphB4 and its 
specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol 
Cell, 1999. 4(3): p. 403-14. 
51. Duffy, S.L., et al., Expression analysis of the Epha1 receptor tyrosine kinase and 
its high-affinity ligands Efna1 and Efna3 during early mouse development. Gene 
Expr Patterns, 2006. 6(7): p. 719-23. 
52. Munoz, J.J., et al., Thymic alterations in EphA4-deficient mice. J Immunol, 2006. 
177(2): p. 804-13. 
53. Miao, H., et al., EphA kinase activation regulates HGF-induced epithelial 
branching morphogenesis. J Cell Biol, 2003. 162(7): p. 1281-92. 
54. Miao, H. and B. Wang, Eph/ephrin signaling in epithelial development and 
homeostasis. Int J Biochem Cell Biol, 2009. 41(4): p. 762-70. 
133 
 
55. Batlle, E., et al., Beta-catenin and TCF mediate cell positioning in the intestinal 
epithelium by controlling the expression of EphB/ephrinB. Cell, 2002. 111(2): p. 
251-63. 
56. Hens, J.R. and J.J. Wysolmerski, Key stages of mammary gland development: 
molecular mechanisms involved in the formation of the embryonic mammary 
gland. Breast Cancer Res, 2005. 7(5): p. 220-4. 
57. Sternlicht, M.D., et al., Hormonal and local control of mammary branching 
morphogenesis. Differentiation, 2006. 74(7): p. 365-81. 
58. Sternlicht, M.D., et al., Mammary ductal morphogenesis requires paracrine 
activation of stromal EGFR via ADAM17-dependent shedding of epithelial 
amphiregulin. Development, 2005. 132(17): p. 3923-33. 
59. Williams, J.M. and C.W. Daniel, Mammary ductal elongation: differentiation of 
myoepithelium and basal lamina during branching morphogenesis. Dev Biol, 
1983. 97(2): p. 274-90. 
60. Smith, G.H. and G. Chepko, Mammary epithelial stem cells. Microsc Res Tech, 
2001. 52(2): p. 190-203. 
61. Kordon, E.C. and G.H. Smith, An entire functional mammary gland may comprise 
the progeny from a single cell. Development, 1998. 125(10): p. 1921-30. 
62. Kim, N.D., et al., Stem cell characteristics of transplanted rat mammary 
clonogens. Exp Cell Res, 2000. 260(1): p. 146-59. 
63. DeOme, K.B. and D. Medina, A new approach to mammary tumorigenesis in 
rodents. Cancer, 1969. 24(6): p. 1255-8. 
64. Hennighausen, L. and G.W. Robinson, Information networks in the mammary 
gland. Nat Rev Mol Cell Biol, 2005. 6(9): p. 715-25. 
65. Nikolova, Z., et al., Cell-type specific and estrogen dependent expression of the 
receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland 
morphogenesis. J Cell Sci, 1998. 111 ( Pt 18): p. 2741-51. 
134 
 
66. Munarini, N., et al., Altered mammary epithelial development, pattern formation 
and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. 
J Cell Sci, 2002. 115(Pt 1): p. 25-37. 
67. Kouros-Mehr, H. and Z. Werb, Candidate regulators of mammary branching 
morphogenesis identified by genome-wide transcript analysis. Dev Dyn, 2006. 
235(12): p. 3404-12. 
68. Andres, A.C., et al., Expression of two novel eph-related receptor protein tyrosine 
kinases in mammary gland development and carcinogenesis. Oncogene, 1994. 
9(5): p. 1461-7. 
69. Vaught, D., J. Chen, and D.M. Brantley-Sieders, Regulation of mammary gland 
branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell, 
2009. 20(10): p. 2572-81. 
70. Ogawa, K., et al., The ephrin-A1 ligand and its receptor, EphA2, are expressed 
during tumor neovascularization. Oncogene, 2000. 19(52): p. 6043-52. 
71. Zelinski, D.P., et al., EphA2 overexpression causes tumorigenesis of mammary 
epithelial cells. Cancer Res, 2001. 61(5): p. 2301-6. 
72. Martin, K.J., et al., Prognostic breast cancer signature identified from 3D culture 
model accurately predicts clinical outcome across independent datasets. PLoS 
One, 2008. 3(8): p. e2994. 
73. Fournier, M.V., et al., Gene expression signature in organized and growth-
arrested mammary acini predicts good outcome in breast cancer. Cancer Res, 
2006. 66(14): p. 7095-102. 
74. Ireton, R.C. and J. Chen, EphA2 receptor tyrosine kinase as a promising target 
for cancer therapeutics. Curr Cancer Drug Targets, 2005. 5(3): p. 149-57. 
75. Brantley-Sieders, D., et al., Eph receptor tyrosine kinases in tumor and tumor 
microenvironment. Curr Pharm Des, 2004. 10(27): p. 3431-42. 
76. Brannan, J.M., et al., Expression of the receptor tyrosine kinase EphA2 is 
increased in smokers and predicts poor survival in non-small cell lung cancer. 
Clin Cancer Res, 2009. 15(13): p. 4423-30. 
135 
 
77. Miyazaki, T., et al., EphA2 overexpression correlates with poor prognosis in 
esophageal squamous cell carcinoma. Int J Cancer, 2003. 103(5): p. 657-63. 
78. Wu, D., et al., Prognostic value of EphA2 and EphrinA-1 in squamous cell 
cervical carcinoma. Gynecol Oncol, 2004. 94(2): p. 312-9. 
79. Herrem, C.J., et al., Expression of EphA2 is prognostic of disease-free interval 
and overall survival in surgically treated patients with renal cell carcinoma. Clin 
Cancer Res, 2005. 11(1): p. 226-31. 
80. Wang, L.F., et al., Increased expression of EphA2 correlates with adverse 
outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep, 
2008. 19(1): p. 151-6. 
81. Kamat, A.A., et al., EphA2 overexpression is associated with lack of hormone 
receptor expression and poor outcome in endometrial cancer. Cancer, 2009. 
115(12): p. 2684-92. 
82. Oki, M., et al., Overexpression of the receptor tyrosine kinase EphA4 in human 
gastric cancers. World J Gastroenterol, 2008. 14(37): p. 5650-6. 
83. Wang, L.F., et al., Increased expression of EphA7 correlates with adverse 
outcome in primary and recurrent glioblastoma multiforme patients. BMC 
Cancer, 2008. 8: p. 79. 
84. Kumar, S.R., et al., The receptor tyrosine kinase EphB4 is overexpressed in 
ovarian cancer, provides survival signals and predicts poor outcome. Br J 
Cancer, 2007. 96(7): p. 1083-91. 
85. Masood, R., et al., EphB4 provides survival advantage to squamous cell 
carcinoma of the head and neck. Int J Cancer, 2006. 119(6): p. 1236-48. 
86. Fox, B.P. and R.P. Kandpal, Invasiveness of breast carcinoma cells and transcript 
profile: Eph receptors and ephrin ligands as molecular markers of potential 
diagnostic and prognostic application. Biochem Biophys Res Commun, 2004. 
318(4): p. 882-92. 
87. Wu, Q., et al., Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol 
Res, 2004. 10(1): p. 26-33. 
136 
 
88. Brantley, D.M., et al., Soluble Eph A receptors inhibit tumor angiogenesis and 
progression in vivo. Oncogene, 2002. 21(46): p. 7011-26. 
89. Duxbury, M.S., et al., EphA2: a determinant of malignant cellular behavior and a 
potential therapeutic target in pancreatic adenocarcinoma. Oncogene, 2004. 
23(7): p. 1448-56. 
90. Landen, C.N., Jr., et al., Therapeutic EphA2 gene targeting in vivo using neutral 
liposomal small interfering RNA delivery. Cancer Res, 2005. 65(15): p. 6910-8. 
91. Nasreen, N., K.A. Mohammed, and V.B. Antony, Silencing the receptor EphA2 
suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer, 
2006. 107(10): p. 2425-35. 
92. Kumar, S.R., et al., Receptor tyrosine kinase EphB4 is a survival factor in breast 
cancer. Am J Pathol, 2006. 169(1): p. 279-93. 
93. van de Vijver, M.J., et al., A gene-expression signature as a predictor of survival 
in breast cancer. N Engl J Med, 2002. 347(25): p. 1999-2009. 
94. Kikawa, K.D., et al., Regulation of the EphA2 kinase by the low molecular weight 
tyrosine phosphatase induces transformation. J Biol Chem, 2002. 277(42): p. 
39274-9. 
95. Orsulic, S. and R. Kemler, Expression of Eph receptors and ephrins is 
differentially regulated by E-cadherin. J Cell Sci, 2000. 113 ( Pt 10): p. 1793-802. 
96. Marquardt, T., et al., Coexpressed EphA receptors and ephrin-A ligands mediate 
opposing actions on growth cone navigation from distinct membrane domains. 
Cell, 2005. 121(1): p. 127-39. 
97. Noren, N.K. and E.B. Pasquale, Paradoxes of the EphB4 receptor in cancer. 
Cancer Res, 2007. 67(9): p. 3994-7. 
98. Duxbury, M.S., et al., Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic 
adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun, 2004. 
320(4): p. 1096-102. 
137 
 
99. Hu, M., et al., EphA2 induction of fibronectin creates a permissive 
microenvironment for malignant cells. Mol Cancer Res, 2004. 2(10): p. 533-40. 
100. Guo, H., et al., Disruption of EphA2 receptor tyrosine kinase leads to increased 
susceptibility to carcinogenesis in mouse skin. Cancer Res, 2006. 66(14): p. 7050-
8. 
101. Batlle, E., et al., EphB receptor activity suppresses colorectal cancer progression. 
Nature, 2005. 435(7045): p. 1126-30. 
102. Folkman, J., Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 
2002. 29(6 Suppl 16): p. 15-8. 
103. Pandey, A., et al., Role of B61, the ligand for the Eck receptor tyrosine kinase, in 
TNF-alpha-induced angiogenesis. Science, 1995. 268(5210): p. 567-9. 
104. Casanovas, O., et al., Drug resistance by evasion of antiangiogenic targeting of 
VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 2005. 8(4): p. 
299-309. 
105. Brantley-Sieders, D.M., et al., Impaired tumor microenvironment in EphA2-
deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J, 
2005. 19(13): p. 1884-6. 
106. Brantley-Sieders, D.M., et al., EphA2 receptor tyrosine kinase regulates 
endothelial cell migration and vascular assembly through phosphoinositide 3-
kinase-mediated Rac1 GTPase activation. J Cell Sci, 2004. 117(Pt 10): p. 2037-
49. 
107. Hunter, S.G., et al., Essential role of Vav family guanine nucleotide exchange 
factors in EphA receptor-mediated angiogenesis. Mol Cell Biol, 2006. 26(13): p. 
4830-42. 
108. Shin, D., et al., Expression of ephrinB2 identifies a stable genetic difference 
between arterial and venous vascular smooth muscle as well as endothelial cells, 
and marks subsets of microvessels at sites of adult neovascularization. Dev Biol, 
2001. 230(2): p. 139-50. 
138 
 
109. Noren, N.K., et al., Interplay between EphB4 on tumor cells and vascular ephrin-
B2 regulates tumor growth. Proc Natl Acad Sci U S A, 2004. 101(15): p. 5583-8. 
110. Martiny-Baron, G., et al., Inhibition of tumor growth and angiogenesis by soluble 
EphB4. Neoplasia, 2004. 6(3): p. 248-57. 
111. Sawai, Y., et al., Expression of ephrin-B1 in hepatocellular carcinoma: possible 
involvement in neovascularization. J Hepatol, 2003. 39(6): p. 991-6. 
112. Nagashima, T., et al., Phosphoproteome and transcriptome analyses of ErbB 
ligand-stimulated MCF-7 cells. Cancer Genomics Proteomics, 2008. 5(3-4): p. 
161-8. 
113. Carles-Kinch, K., et al., Antibody targeting of the EphA2 tyrosine kinase inhibits 
malignant cell behavior. Cancer Res, 2002. 62(10): p. 2840-7. 
114. Mundy, G.R., Metastasis to bone: causes, consequences and therapeutic 
opportunities. Nat Rev Cancer, 2002. 2(8): p. 584-93. 
115. Chambers, A.F., A.C. Groom, and I.C. MacDonald, Dissemination and growth of 
cancer cells in metastatic sites. Nat Rev Cancer, 2002. 2(8): p. 563-72. 
116. Massague, J., Sorting out breast-cancer gene signatures. N Engl J Med, 2007. 
356(3): p. 294-7. 
117. Paget, S., The distribution of secondary growths in cancer of the breast. Lancet, 
1889. 1: p. 571-573. 
118. Mundy, G.R., Mechanisms of bone metastasis. Cancer, 1997. 80(8 Suppl): p. 
1546-56. 
119. Hadjidakis, D.J. and Androulakis, II, Bone remodeling. Ann N Y Acad Sci, 2006. 
1092: p. 385-96. 
120. Karsenty, G., The complexities of skeletal biology. Nature, 2003. 423(6937): p. 
316-8. 
139 
 
121. Ara, T. and Y.A. DeClerck, Mechanisms of invasion and metastasis in human 
neuroblastoma. Cancer Metastasis Rev, 2006. 25(4): p. 645-57. 
122. Karsenty, G. and E.F. Wagner, Reaching a genetic and molecular understanding 
of skeletal development. Dev Cell, 2002. 2(4): p. 389-406. 
123. Bussard, K.M., C.V. Gay, and A.M. Mastro, The bone microenvironment in 
metastasis; what is special about bone? Cancer Metastasis Rev, 2008. 27(1): p. 
41-55. 
124. Bergfeld, S.A. and Y.A. DeClerck, Bone marrow-derived mesenchymal stem cells 
and the tumor microenvironment. Cancer Metastasis Rev, 2010. 29(2): p. 249-61. 
125. Tatsumi, S., et al., Targeted ablation of osteocytes induces osteoporosis with 
defective mechanotransduction. Cell Metab, 2007. 5(6): p. 464-75. 
126. Bonewald, L.F., Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci, 
2007. 1116: p. 281-90. 
127. Teitelbaum, S.L., Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res 
Ther, 2006. 8(1): p. 201. 
128. Teitelbaum, S.L., Osteoclasts: what do they do and how do they do it? Am J 
Pathol, 2007. 170(2): p. 427-35. 
129. Kodama, H., et al., Essential role of macrophage colony-stimulating factor in the 
osteoclast differentiation supported by stromal cells. J Exp Med, 1991. 173(5): p. 
1291-4. 
130. Teitelbaum, S.L. and F.P. Ross, Genetic regulation of osteoclast development and 
function. Nat Rev Genet, 2003. 4(8): p. 638-49. 
131. Zaidi, M., Skeletal remodeling in health and disease. Nat Med, 2007. 13(7): p. 
791-801. 
132. Matsuo, K. and N. Irie, Osteoclast-osteoblast communication. Arch Biochem 
Biophys, 2008. 473(2): p. 201-9. 
140 
 
133. Pfeilschifter, J. and G.R. Mundy, Modulation of type beta transforming growth 
factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S 
A, 1987. 84(7): p. 2024-8. 
134. Kong, Y.Y., et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte 
development and lymph-node organogenesis. Nature, 1999. 397(6717): p. 315-23. 
135. Li, J., et al., RANK is the intrinsic hematopoietic cell surface receptor that 
controls osteoclastogenesis and regulation of bone mass and calcium metabolism. 
Proc Natl Acad Sci U S A, 2000. 97(4): p. 1566-71. 
136. Simonet, W.S., et al., Osteoprotegerin: a novel secreted protein involved in the 
regulation of bone density. Cell, 1997. 89(2): p. 309-19. 
137. Guise, T.A. and G.R. Mundy, Cancer and bone. Endocr Rev, 1998. 19(1): p. 18-
54. 
138. Compagni, A., et al., Control of skeletal patterning by ephrinB1-EphB 
interactions. Dev Cell, 2003. 5(2): p. 217-30. 
139. Davy, A., J. Aubin, and P. Soriano, Ephrin-B1 forward and reverse signaling are 
required during mouse development. Genes Dev, 2004. 18(5): p. 572-83. 
140. Xing, W., et al., Ephrin B1 regulates bone marrow stromal cell differentiation 
and bone formation by influencing TAZ transactivation via complex formation 
with NHERF1. Mol Cell Biol, 2010. 30(3): p. 711-21. 
141. Wieland, I., et al., Mutations of the ephrin-B1 gene cause craniofrontonasal 
syndrome. Am J Hum Genet, 2004. 74(6): p. 1209-15. 
142. Twigg, S.R., et al., Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary 
formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci U S A, 2004. 
101(23): p. 8652-7. 
143. Zhao, C., et al., Bidirectional ephrinB2-EphB4 signaling controls bone 
homeostasis. Cell Metab, 2006. 4(2): p. 111-21. 
141 
 
144. Ting, M.C., et al., EphA4 as an effector of Twist1 in the guidance of osteogenic 
precursor cells during calvarial bone growth and in craniosynostosis. 
Development, 2009. 136(5): p. 855-64. 
145. Irie, N., et al., Bidirectional signaling through ephrinA2-EphA2 enhances 
osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem, 2009. 
284(21): p. 14637-44. 
146. Liao, J. and L.K. McCauley, Skeletal metastasis: Established and emerging roles 
of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev, 2006. 
25(4): p. 559-71. 
147. Morrissey, C., et al., Differential expression of angiogenesis associated genes in 
prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis, 
2008. 25(4): p. 377-88. 
148. Guenther, R., et al., Giant cell tumors of the bone: molecular profiling and 
expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. 
Pathol Res Pract, 2005. 201(10): p. 649-63. 
149. Taddei, M.L., et al., Kinase-dependent and -independent roles of EphA2 in the 
regulation of prostate cancer invasion and metastasis. Am J Pathol, 2009. 174(4): 
p. 1492-503. 
150. Sims, N.A. and J.H. Gooi, Bone remodeling: Multiple cellular interactions 
required for coupling of bone formation and resorption. Semin Cell Dev Biol, 
2008. 19(5): p. 444-51. 
151. Guise, T.A. and J.M. Chirgwin, Transforming growth factor-beta in osteolytic 
breast cancer bone metastases. Clin Orthop Relat Res, 2003(415 Suppl): p. S32-
8. 
152. Pederson, L., et al., Identification of breast cancer cell line-derived paracrine 
factors that stimulate osteoclast activity. Cancer Res, 1999. 59(22): p. 5849-55. 
153. Jimi, E., et al., Interleukin 1 induces multinucleation and bone-resorbing activity 
of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res, 1999. 
247(1): p. 84-93. 
142 
 
154. Coffman, K.T., et al., Differential EphA2 epitope display on normal versus 
malignant cells. Cancer Res, 2003. 63(22): p. 7907-12. 
155. Hammond, S.A., et al., Selective targeting and potent control of tumor growth 
using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res, 
2007. 67(8): p. 3927-35. 
156. Wykosky, J., D.M. Gibo, and W. Debinski, A novel, potent, and specific 
ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol 
Cancer Ther, 2007. 6(12 Pt 1): p. 3208-18. 
157. Jackson, D., et al., A human antibody-drug conjugate targeting EphA2 inhibits 
tumor growth in vivo. Cancer Res, 2008. 68(22): p. 9367-74. 
158. Landen, C.N., et al., Intraperitoneal delivery of liposomal siRNA for therapy of 
advanced ovarian cancer. Cancer Biol Ther, 2006. 5(12): p. 1708-13. 
159. Cheng, N., et al., Inhibition of VEGF-dependent multistage carcinogenesis by 
soluble EphA receptors. Neoplasia, 2003. 5(5): p. 445-56. 
160. Dobrzanski, P., et al., Antiangiogenic and antitumor efficacy of EphA2 receptor 
antagonist. Cancer Res, 2004. 64(3): p. 910-9. 
161. Noberini, R., et al., Small molecules can selectively inhibit ephrin binding to the 
EphA4 and EphA2 receptors. J Biol Chem, 2008. 283(43): p. 29461-72. 
162. Chrencik, J.E., et al., Three-dimensional structure of the EphB2 receptor in 
complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol 
Chem, 2007. 282(50): p. 36505-13. 
163. Tatsumi, T., et al., Disease stage variation in CD4+ and CD8+ T-cell reactivity 
to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. 
Cancer Res, 2003. 63(15): p. 4481-9. 
164. Yamaguchi, S., et al., Immunotherapy of murine colon cancer using receptor 
tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer, 
2007. 110(7): p. 1469-77. 
143 
 
165. Hatano, M., et al., Vaccination with EphA2-derived T cell-epitopes promotes 
immunity against both EphA2-expressing and EphA2-negative tumors. J Transl 
Med, 2004. 2(1): p. 40. 
166. Pasquale, E.B., Eph receptors and ephrins in cancer: bidirectional signalling and 
beyond. Nat Rev Cancer, 2010. 10(3): p. 165-80. 
167. Vaught, D., D.M. Brantley-Sieders, and J. Chen, Eph receptors in breast cancer: 
roles in tumor promotion and tumor suppression. Breast Cancer Res, 2008. 10(6): 
p. 217. 
168. Bardelle, C., et al., Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-
based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg 
Med Chem Lett, 2008. 18(9): p. 2776-80. 
169. Miyazaki, Y., et al., Design and effective synthesis of novel templates, 3,7-
diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors 
and in vitro evaluation targeting angiogenetic kinases. Bioorg Med Chem Lett, 
2007. 17(1): p. 250-4. 
170. Bardelle, C., et al., Inhibitors of the tyrosine kinase EphB4. Part 2: structure-
based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. 
Bioorg Med Chem Lett, 2008. 18(21): p. 5717-21. 
171. Lafleur, K., et al., Structure-based optimization of potent and selective inhibitors 
of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma 
receptor B4 (EphB4). J Med Chem, 2009. 52(20): p. 6433-46. 
172. Kolb, P., et al., Discovery of kinase inhibitors by high-throughput docking and 
scoring based on a transferable linear interaction energy model. J Med Chem, 
2008. 51(5): p. 1179-88. 
173. Wang, X.D., et al., Identification of candidate predictive and surrogate molecular 
markers for dasatinib in prostate cancer: rationale for patient selection and 
efficacy monitoring. Genome Biol, 2007. 8(11): p. R255. 
174. Huang, F., et al., Identification of candidate molecular markers predicting 
sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer 
Res, 2007. 67(5): p. 2226-38. 
144 
 
175. Karaman, M.W., et al., A quantitative analysis of kinase inhibitor selectivity. Nat 
Biotechnol, 2008. 26(1): p. 127-32. 
176. Choi, Y., et al., Discovery and structural analysis of Eph receptor tyrosine kinase 
inhibitors. Bioorg Med Chem Lett, 2009. 19(15): p. 4467-70. 
177. Shahzad, M.M., et al., Dual targeting of EphA2 and FAK in ovarian carcinoma. 
Cancer Biol Ther, 2009. 8(11): p. 1027-34. 
178. Xia, G., et al., EphB4 receptor tyrosine kinase is expressed in bladder cancer and 
provides signals for cell survival. Oncogene, 2006. 25(5): p. 769-80. 
179. Xia, G., et al., EphB4 expression and biological significance in prostate cancer. 
Cancer Res, 2005. 65(11): p. 4623-32. 
180. Kumar, S.R., et al., Preferential induction of EphB4 over EphB2 and its 
implication in colorectal cancer progression. Cancer Res, 2009. 69(9): p. 3736-
45. 
181. Cheng, N., et al., Blockade of EphA receptor tyrosine kinase activation inhibits 
vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res, 
2002. 1(1): p. 2-11. 
182. Kertesz, N., et al., The soluble extracellular domain of EphB4 (sEphB4) 
antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits 
tumor growth. Blood, 2006. 107(6): p. 2330-8. 
183. Scehnet, J.S., et al., The role of Ephs, Ephrins, and growth factors in Kaposi 
sarcoma and implications of EphrinB2 blockade. Blood, 2009. 113(1): p. 254-63. 
184. Murai, K.K., et al., Targeting the EphA4 receptor in the nervous system with 
biologically active peptides. Mol Cell Neurosci, 2003. 24(4): p. 1000-11. 
185. Koolpe, M., et al., EphB receptor-binding peptides identified by phage display 
enable design of an antagonist with ephrin-like affinity. J Biol Chem, 2005. 
280(17): p. 17301-11. 
145 
 
186. Salvucci, O., et al., EphrinB reverse signaling contributes to endothelial and 
mural cell assembly into vascular structures. Blood, 2009. 114(8): p. 1707-16. 
187. Chrencik, J.E., et al., Structure and thermodynamic characterization of the 
EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for 
receptor specificity. Structure, 2006. 14(2): p. 321-30. 
188. Qin, H., et al., Crystal structure and NMR binding reveal that two small molecule 
antagonists target the high affinity ephrin-binding channel of the EphA4 receptor. 
J Biol Chem, 2008. 283(43): p. 29473-84. 
189. Mao, W., et al., EphB2 as a therapeutic antibody drug target for the treatment of 
colorectal cancer. Cancer Res, 2004. 64(3): p. 781-8. 
190. Landen, C.N., Jr., et al., Efficacy and antivascular effects of EphA2 reduction with 
an agonistic antibody in ovarian cancer. J Natl Cancer Inst, 2006. 98(21): p. 
1558-70. 
191. Bruckheimer, E.M., et al., Antibody-dependent cell-mediated cytotoxicity effector-
enhanced EphA2 agonist monoclonal antibody demonstrates potent activity 
against human tumors. Neoplasia, 2009. 11(6): p. 509-17, 2 p following 517. 
192. Kiewlich, D., et al., Anti-EphA2 antibodies decrease EphA2 protein levels in 
murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit 
tumor growth. Neoplasia, 2006. 8(1): p. 18-30. 
193. van Geer, M.A., et al., Ephrin A2 receptor targeting does not increase adenoviral 
pancreatic cancer transduction in vivo. World J Gastroenterol, 2009. 15(22): p. 
2754-62. 
194. Noblitt, L.W., et al., Decreased tumorigenic potential of EphA2-overexpressing 
breast cancer cells following treatment with adenoviral vectors that express 
EphrinA1. Cancer Gene Ther, 2004. 11(11): p. 757-66. 
195. Gobin, A.M., J.J. Moon, and J.L. West, EphrinA I-targeted nanoshells for 
photothermal ablation of prostate cancer cells. Int J Nanomedicine, 2008. 3(3): p. 
351-8. 
146 
 
196. Cai, W., et al., Quantitative radioimmunoPET imaging of EphA2 in tumor-
bearing mice. Eur J Nucl Med Mol Imaging, 2007. 34(12): p. 2024-36. 
197. Scarberry, K.E., et al., Selective removal of ovarian cancer cells from human 
ascites fluid using magnetic nanoparticles. Nanomedicine, 2009. 6(3): p. 399-408. 
198. Scarberry, K.E., et al., Magnetic nanoparticle-peptide conjugates for in vitro and 
in vivo targeting and extraction of cancer cells. J Am Chem Soc, 2008. 130(31): 
p. 10258-62. 
199. Vearing, C., et al., Concurrent binding of anti-EphA3 antibody and ephrin-A5 
amplifies EphA3 signaling and downstream responses: potential as EphA3-
specific tumor-targeting reagents. Cancer Res, 2005. 65(15): p. 6745-54. 
200. Scott, J.D. and T. Pawson, Cell signaling in space and time: where proteins come 
together and when they're apart. Science, 2009. 326(5957): p. 1220-4. 
201. Watson, C.J. and W.T. Khaled, Mammary development in the embryo and adult: 
a journey of morphogenesis and commitment. Development, 2008. 135(6): p. 995-
1003. 
202. Pollard, J.W., Tumour-stromal interactions. Transforming growth factor-beta 
isoforms and hepatocyte growth factor/scatter factor in mammary gland ductal 
morphogenesis. Breast Cancer Res, 2001. 3(4): p. 230-7. 
203. Kamalati, T., et al., HGF/SF in mammary epithelial growth and morphogenesis: 
in vitro and in vivo models. J Mammary Gland Biol Neoplasia, 1999. 4(1): p. 69-
77. 
204. Andres, A.C., et al., EphB4 receptor tyrosine kinase transgenic mice develop 
glomerulopathies reminiscent of aglomerular vascular shunts. Mech Dev, 2003. 
120(4): p. 511-6. 
205. Murai, K.K., et al., Control of hippocampal dendritic spine morphology through 
ephrin-A3/EphA4 signaling. Nat Neurosci, 2003. 6(2): p. 153-60. 
206. Brantley-Sieders, D.M. and J. Chen, Eph receptor tyrosine kinases in 
angiogenesis: from development to disease. Angiogenesis, 2004. 7(1): p. 17-28. 
147 
 
207. Poliakov, A., M. Cotrina, and D.G. Wilkinson, Diverse roles of eph receptors and 
ephrins in the regulation of cell migration and tissue assembly. Dev Cell, 2004. 
7(4): p. 465-80. 
208. Kinch, M.S. and K. Carles-Kinch, Overexpression and functional alterations of 
the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis, 2003. 20(1): p. 59-68. 
209. Brantley, D.M., et al., Nuclear factor-kappaB (NF-kappaB) regulates 
proliferation and branching in mouse mammary epithelium. Mol Biol Cell, 2001. 
12(5): p. 1445-55. 
210. Debnath, J., S.J. Walker, and J.S. Brugge, Akt activation disrupts mammary 
acinar architecture and enhances proliferation in an mTOR-dependent manner. J 
Cell Biol, 2003. 163(2): p. 315-26. 
211. Muraoka, R.S., et al., Increased malignancy of Neu-induced mammary tumors 
overexpressing active transforming growth factor beta1. Mol Cell Biol, 2003. 
23(23): p. 8691-703. 
212. Wiseman, B.S. and Z. Werb, Stromal effects on mammary gland development and 
breast cancer. Science, 2002. 296(5570): p. 1046-9. 
213. Ridley, A.J., Rho family proteins: coordinating cell responses. Trends Cell Biol, 
2001. 11(12): p. 471-7. 
214. Ridley, A.J., Rho GTPases and cell migration. J Cell Sci, 2001. 114(Pt 15): p. 
2713-22. 
215. Ridley, A.J., Rho proteins, PI 3-kinases, and monocyte/macrophage motility. 
FEBS Lett, 2001. 498(2-3): p. 168-71. 
216. Ewald, A.J., et al., Collective epithelial migration and cell rearrangements drive 
mammary branching morphogenesis. Dev Cell, 2008. 14(4): p. 570-81. 
217. Sternlicht, M.D., Key stages in mammary gland development: the cues that 
regulate ductal branching morphogenesis. Breast Cancer Res, 2006. 8(1): p. 201. 
148 
 
218. Chakravarty, G., et al., P190-B, a Rho-GTPase-activating protein, is differentially 
expressed in terminal end buds and breast cancer. Cell Growth Differ, 2000. 
11(7): p. 343-54. 
219. Vargo-Gogola, T., et al., P190-B Rho GTPase-activating protein overexpression 
disrupts ductal morphogenesis and induces hyperplastic lesions in the developing 
mammary gland. Mol Endocrinol, 2006. 20(6): p. 1391-405. 
220. Coleman, R.E., et al., Biochemical prediction of response of bone metastases to 
treatment. Br J Cancer, 1988. 58(2): p. 205-10. 
221. Davy, A. and P. Soriano, Ephrin signaling in vivo: look both ways. Dev Dyn, 
2005. 232(1): p. 1-10. 
222. Lynch, C.C., et al., MMP-7 promotes prostate cancer-induced osteolysis via the 
solubilization of RANKL. Cancer Cell, 2005. 7(5): p. 485-96. 
223. Thiolloy, S., et al., Osteoclast-derived matrix metalloproteinase-7, but not matrix 
metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res, 2009. 
69(16): p. 6747-55. 
224. Mitsiades, C.S., et al., The role of the bone microenvironment in the 
pathophysiology and therapeutic management of multiple myeloma: interplay of 
growth factors, their receptors and stromal interactions. Eur J Cancer, 2006. 
42(11): p. 1564-73. 
225. Fukaya, Y., et al., Identification of galectin-3-binding protein as a factor secreted 
by tumor cells that stimulates interleukin-6 expression in the bone marrow 
stroma. J Biol Chem, 2008. 283(27): p. 18573-81. 
226. Chen, J., et al., Eph receptors and Ephrins in cancer: common themes and 
controversies. Cancer Res, 2008. 68(24): p. 10031-3. 
227. Pasquale, E.B., Eph-ephrin promiscuity is now crystal clear. Nat Neurosci, 2004. 
7(5): p. 417-8. 
228. Lee, H.S., et al., EphrinB1 controls cell-cell junctions through the Par polarity 
complex. Nat Cell Biol, 2008. 10(8): p. 979-86. 
149 
 
229. Li, J.J., et al., EphrinA5 acts as a tumor suppressor in glioma by negative 
regulation of epidermal growth factor receptor. Oncogene, 2009. 28(15): p. 1759-
68. 
230. Campbell, T.N., et al., Ephrin A5 expression promotes invasion and 
transformation of murine fibroblasts. Biochem Biophys Res Commun, 2006. 
350(3): p. 623-8. 
231. Xu, N.J. and M. Henkemeyer, Ephrin-B3 reverse signaling through Grb4 and 
cytoskeletal regulators mediates axon pruning. Nat Neurosci, 2009. 12(3): p. 268-
76. 
232. Jiang, G., et al., In human leukemia cells ephrin-B-induced invasive activity is 
supported by Lck and is associated with reassembling of lipid raft signaling 
complexes. Mol Cancer Res, 2008. 6(2): p. 291-305. 
233. Nakada, M., et al., Ephrin-B3 ligand promotes glioma invasion through activation 
of Rac1. Cancer Res, 2006. 66(17): p. 8492-500. 
234. Lindberg, R.A. and T. Hunter, cDNA cloning and characterization of eck, an 
epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein 
kinases. Mol Cell Biol, 1990. 10(12): p. 6316-24. 
235. Cheng, N., D.M. Brantley, and J. Chen, The ephrins and Eph receptors in 
angiogenesis. Cytokine Growth Factor Rev, 2002. 13(1): p. 75-85. 
236. Garcia, T., et al., A convenient clinically relevant model of human breast cancer 
bone metastasis. Clin Exp Metastasis, 2008. 25(1): p. 33-42. 
237. Kang, Y., et al., A multigenic program mediating breast cancer metastasis to 
bone. Cancer Cell, 2003. 3(6): p. 537-49. 
238. Eckhardt, B.L., et al., Genomic analysis of a spontaneous model of breast cancer 
metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res, 
2005. 3(1): p. 1-13. 
 
 
